L ; 24-2594 Rutledge v. Walgreen Co.

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
UNITED S TATES C OURT OF APPEALS 1
FOR THE SECOND C IRCUIT 2
3
August Term 2025 4
Argued: November 17, 2025 Decided: July 13, 2026 5
Docket Nos. 24-916-cv(L), 24-1121(Con), 24-2360(Con); 24-2594-cv 6
7
8
TIFFANY RUTLEDGE , INDIVIDUALLY AND AS MOTHER , GENERAL GUARDIAN OF , 9
ET AL ., KRISTOPHER WHITE , BRIDGET MCC ONNELL , ALEXANDER H OLLAND, 10
C HRISTINE H OLLAND, 11
Plaintiffs-Appellants, 12
13
v. 14
15
WALGREEN C O., C OSTCO WHOLESALE C ORPORATION, CVS HEALTH 16
C ORPORATION, CVS PHARMACY , INC., S AFEWAY INC., WALMART INC., A D ELAWARE 17
CORPORATION, RITE AID C ORPORATION, FAMILY D OLLAR , INC., TARGET 18
C ORPORATION, S AM’S WEST , INC., D OLLAR TREE , INC., 7-E LEVEN, INC., FAMILY 19
D OLLAR STORES, INC., THE KROGER CO., D OLLAR TREE STORES, INC., J OHNSON & 20
J OHNSON CONSUMER INC., B IG L OTS, GIANT FOOD LLC, ALBERTSON’S, H ARRIS 21
TEETER LLC, DOLGENCORP, LLC, 22
Defendants-Appellees. 23
24
MICHELLE PHIPPEN, INDIVIDUALLY AND AS GENERAL GUARDIAN OF P.P. AND 25
L.A., MINORS, ALISHA D AY , INDIVIDUALLY AND AS MOTHER , GENERAL GUARDIAN OF 26
A.D., A MINOR , S ARAH S TOKES, INDIVIDUALLY AND AS GENERAL GUARDIAN OF K.G., 27
A MINOR , J UAN E MANUEL B ORDOY , INDIVIDUALLY , MARY ELIN ARCE , INDIVIDUALLY 28
AND AS MOTHER OF J UAN E MANUEL B ORDOY , AMANDA TRIGLOFF, INDIVIDUALLY 29
AND AS GENERAL GUARDIAN OF R.S., A MINOR , D EANDRE B ARBEE, INDIVIDUALLY , 30
JANTAIL B ARBEE , INDIVIDUALLY AND AS MOTHER OF D EANDRE B ARBEE , L AURIE 31

-- 1 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
2
C OURINGTON, H UNTER C OURINGTON, JENNIFER MORROW, ALENA MORROW , 1
C ALLISTA B ASSETT , ANDREW B ASSETT , S ONNITA ROBY , INDIVIDUALLY AND AS 2
GENERAL GUARDIAN OF D.P., A MINOR , S HANNON MIKUSKI , B RAYDON MCKENZIE , 3
H EATHER GILLIAM, COLBY GILLIAM, TAYLOR B ROWN, TARYNE B URKE , 4
INDIVIDUALLY AND AS MOTHER WITH COURT - APPOINTED GUARDIAN OF ASHTON 5
B URKE , S AMARI S IMS, INDIVIDUALLY , DENISA C ULLOM, INDIVIDUALLY AND AS 6
MOTHER OF S AMARI SIMS, C OLLIN S TOVER , INDIVIDUALLY , D ANA S TEWART , 7
INDIVIDUALLY AND AS MOTHER OF C OLLING S TOVER , RIAN C ZAR J OHNSON, 8
INDIVIDUALLY , S HILO RICH, INDIVIDUALLY AND AS MOTHER OF RIAN C ZAR 9
JOHNSON, SHEENA S CHNEPP, INDIVIDUALLY AND AS MOTHER AND NATURAL 10
GUARDIAN OF H.S., A MINOR , ZAYNE C OSTELLO, INDIVIDUALLY , CRYSTAL 11
ALEXANDER , C OURTNEY TILLOTSON, MICHELLE B ROWN, 12
Plaintiffs-Appellants, 13
14
v. 15
16
W ALGREEN C O., J OHNSON & J OHNSON C ONSUMER INC., WALMART INC., 17
Defendants-Appellees.* 18
19
20
APPEAL FROM THE UNITED STATES D ISTRICT C OURT 21
FOR THE S OUTHERN DISTRICT OF NEW YORK 22
23
Before: C ALABRESI , L YNCH, and L EE , Circuit Judges. 24
25
Plaintiffs-Appellants appeal from judgments of the U.S. District Court for 26
the Southern District of New York (Denise L. Cote, District Judge), dismissing 27
Plaintiffs-Appellants’ complaints alleging that Defendants-Appellees failed to 28
* The Clerk of Court is respectfully directed to amend the official caption in this case to conform
with the caption above.

-- 2 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
3
warn them that prenatal ingestion of their acetaminophen products could cause 1
attention-deficit/hyperactivity disorder and autism spectrum disorder. In 2
Rutledge, the District Court excluded the general causation evidence offered by 3
Plaintiffs-Appellants’ five experts, Drs. Baccarelli, Hollander, Pearson, Cabrera, 4
and Louie. In Phippen, it excluded the evidence offered by an additional expert, Dr. 5
Ness. The District Court granted summary judgment for Defendants-Appellees in 6
both cases. 7
With respect to expert testimony, the district court serves a “gatekeeping” 8
function—it is charged with “the task of ensuring that an expert’s testimony both 9
rests on a reliable foundation and is relevant to the task at hand.” Daubert v. Merrell 10
Dow Pharms., Inc., 509 U.S. 579, 597 (1993). Where a particular technique or theory 11
has gained general acceptance in the scientific community, and an expert reliably 12
applies that methodology to the subject of inquiry, testimony is admissible. 13
We conclude that the District Court exceeded its discretion by excluding the 14
expert testimony of Drs. Baccarelli, Hollander, and Pearson, but was within its 15
discretion in excluding the testimony of Drs. Cabrera and Louie. In Phippen, we 16
conclude that reconsideration of the exclusion of Dr. Ness’s testimony is 17
warranted in light of our opinion in Rutledge. We further conclude that the District 18
Court correctly declined to dismiss the case on the ground that Plaintiffs- 19
Appellants’ failure-to-warn claims were preempted by federal drug labeling laws. 20
We therefore VACATE and REMAND for further proceedings consistent 21
with this opinion. 22
23
A SHLEY C. KELLER , Keller Postman LLC, Chicago, IL; with 24
Ashley L.F. Barriere, Keller Postman LLC, Chicago, IL; John J. 25
Snidow & Roseann R. Romano, Keller Postman LLC, 26
Washington, DC, for Plaintiffs-Appellants Tiffany Rutledge 27
Kristopher White, Bridget McConnell, Alexander Holland, Christine 28
Holland in Rutledge v. Walgreen Co., and for Plaintiffs-Appellants 29
Sonnita Roby, Taylor Brown, Michelle Phippen, Amanda Trigloff, 30
Laurie Courington, Hunter Courington, Jennifer Morrow, Alena 31
Morrow, Callista Bassett, Andrew Bassett, Shannon Mikuski, 32
Braydon McKenzie, Heather Gilliam, Colby Gilliam, and Michelle 33
Brown in Phippen v. Walgreen Co. 34

-- 3 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
4
Daniel C. Burke, Bernstein Liebhard LLP, New York, NY, for 1
Plaintiffs-Appellants Juan Emanuel Bordoy, Mary Elin Arce, 2
Deandre Barbee, Jantail Barbee, Taryne Burke, Samari Sims, Denisa 3
Cullom, Collin Stover, Dana Stewart, Rian Czar Johnson, Shilo Rich, 4
Sheena Schnepp, Zayne Costello, Crystal Alexander, and Courtney 5
Tillotson. 6
Lindsey Scarcello, Wagstaff & Cartmell, LLP, Kansas City, MO, 7
for Plaintiff-Appellant Alisha Day. 8
J AY P. L EFKOWITZ , Kirkland & Ellis LLP, New York, NY; with 9
Cole T. Carter, Kirland & Ellis, LLP, Chicago, IL, for Defendant- 10
Appellee Johnson & Johnson Consumer Inc. 11
Jeffrey S. Bucholtz & Amy R. Upshaw, King & Spalding LLP, 12
Washington, DC; Matthew Noller, King & Spalding LLP, San 13
Francisco, CA for Defendants-Appellees Walmart Inc. and Sam’s 14
West, Inc. 15
Kristen L. Richer, Barnes & Thornburg LLP, Los Angeles, CA, 16
for Defendants-Appellees CVS Pharmacy, Inc., Walgreen Co., and 17
Costco Wholesale Corporation. 18
Amanda Groves, Winston & Strawn LLP, Los Angeles, CA, for 19
Defendants-Appellees Safeway, Inc., and Albertsons Companies, Inc. 20
Joseph A. Lara, Stone | Dean LLP, Woodland Hills, CA, for 21
Defendant-Appellee The Kroger Company. 22
Lori B. Leskin & Mitchell Russell Stern, Arnold & Porter Kaye 23
Scholer LLP, New York, NY; William C. Perdue & Anthony J. 24
Franze, Arnold & Porter Kaye Scholer LLP, Washington, DC, 25
for Defendants-Appellees 7-Eleven, Inc., Dollar Tree Stores, Inc., and 26
Family Dollar Stores, LLC. 27
Anne A. Gruner, Duane Morris LLP, Philadelphia, PA, for 28
Defendant-Appellee Dolgencorp, LLC. 29
Deanne E. Maynard, Morrison & Foerster LLP, Washington, 30
DC; Julie Y. Park & Alexandra Preece Barlow, Morrison & 31
Foerster LLP, San Diego, CA; Alexandra M. Avvocato, 32

-- 4 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
5
Morrison & Foerster LLP, New York, NY, for Defendant-Appellee 1
Target Corporation. 2
Jeffrey R. White, American Association for Justice, Washington 3
DC, for Amicus Curiae American Association for Justice, in support 4
of Plaintiffs-Appellants. 5
Lawrence P. Eagel, J. Brandon Walker, and Marion C. 6
Passmore, Bragar Eagel & Squire, P.C., New York, NY, for Amici 7
Curiae Law Professors Anne Bloom, Erwin Chemerinsky, Valerie P. 8
Hans, and Richard L. Jolly, in support of Plaintiffs-Appellants. 9
John R. Byrne, Maderal Byrne & Furst PLLC, Coral Gables, FL, 10
for Amici Curiae Epidemiologists Yinong Young-Xu, Marc 11
Weisskopf, and Graham Colditz, in support of Plaintiffs-Appellants. 12
Jennifer B. Dickey & Mariel A. Brookins, Chamber of 13
Commerce of the United States of America, Washington, DC; 14
Joshua J. Fougere & Madeleine Joseph, Sidley Austin LLP, 15
Washington, DC, for Amicus Curiae Chamber of Commerce of the 16
United States, in support of Defendants-Appellees. 17
Raffi Melkonian, Wright, Close & Barger LLP, Houston, TX, for 18
Amicus Curiae Lawyers for Civil Justice, in support of Defendants- 19
Appellees. 20
21
C ALABRESI , Circuit Judge: 22
Plaintiffs-Appellants in these tandem cases bring failure-to-warn claims 23
under state law relating to acetaminophen, the active ingredient in Tylenol and its 24
generic equivalents. They are children, parents, and guardians who allege that 25
prenatal ingestion of acetaminophen caused them or their children to develop 26
attention-deficit/hyperactivity disorder (“ADHD”) and/or autism spectrum 27
disorder (“ASD”). Defendants-Appellees are the pharmaceutical companies, 28

-- 5 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
6
pharmacies, and retailers involved in the manufacturing, marketing, and/or sale 1
of acetaminophen products. 2
In the cases underlying the first appeal, Rutledge v. Walgreen Co., Plaintiffs- 3
Appellants relied on the general causation testimony of five experts—Dr. Andrea 4
Baccarelli, M.D., Ph.D., Dr. Eric Hollander, M.D., Dr. Brandon Pearson, Ph.D., Dr. 5
Robert Cabrera, Ph.D., and Dr. Stan Louie, Pharm.D.—who opined as to a possible 6
causal relationship between prenatal acetaminophen use and ADHD and ASD. 7
The district court excluded the testimony of those five experts and granted 8
summary judgment to Defendants-Appellees. 9
The second appeal, Phippen v. Walgreen Co., involves a separate group of 10
Plaintiffs-Appellants alleging injury solely from ADHD. After the district court’s 11
initial ruling, those Plaintiffs-Appellants introduced an additional expert, Dr. 12
Roberta Ness, M.D., M.P.H., to testify as to a possible causal relationship between 13
prenatal acetaminophen use and ADHD only. The district court excluded her 14
testimony and granted summary judgment to Defendants-Appellees. We consider 15
these appeals together because of the substantial overlap of the issues they present. 16
These appeals concern what qualifies as admissible epidemiological 17
testimony in support of a general causal relationship. They arise against the 18
backdrop of significant debate in the relevant scientific communities. That debate 19
has also become political. But the issue before us is not political. It is not about 20
positions taken by elected officials or political appointees. Nor do these appeals 21
require us to decide whether acetaminophen use during pregnancy has adverse 22
effects on fetal development. The issues before us concern the rules of evidence, 23

-- 6 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
7
specifically the requirements for the admissibility of expert testimony. And so it is 1
important that before we begin, we make clear what we are deciding and what we 2
are not. 3
We are not deciding whether there is a general causal relationship between 4
acetaminophen and ADHD and/or ASD. We are also not deciding whether the 5
manufacturers of acetaminophen must warn consumers about any alleged risk 6
posed by such a potential causal relationship. And we are certainly not deciding 7
the approach that policymakers concerned with protecting public health should 8
take to regulating the use of acetaminophen. Rather, we are called upon to decide 9
how closely a trial court may scrutinize a qualified expert’s conclusions when that 10
expert follows methodologies that are generally accepted in their field, and the 11
standard of reliability required for the admission of expert testimony on issues 12
that are the subject of ongoing scientific debate. 13
We conclude that, in Rutledge v. Walgreen Co., the district court exceeded its 14
discretion in excluding the expert testimony of Drs. Baccarelli, Hollander, and 15
Pearson. Those concededly qualified experts offered opinions that comport with 16
methodologies applied by other scientists in their fields, and constitute acceptable 17
interpretations of scientific evidence where scientists may, and in fact do, disagree 18
on the ultimate answer to the causal question that they are assessing. 19
The district court did not, however, abuse its discretion in excluding the 20
testimony of Drs. Cabrera and Louie. The district court was entitled to conclude 21
that Cabrera’s opinion was unreliable because it did not weigh or properly 22
synthesize the factors under the so-called Bradford Hill methodology that he 23

-- 7 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
8
employed. And the district court was similarly entitled to conclude that Louie’s 1
opinion did not reliably address the dose and duration exposure threshold for risk 2
of ADHD and ASD because he failed to explain how he extrapolated from the 3
studies he analyzed to reach his final conclusion. We therefore vacate and remand 4
the district court’s judgment in Rutledge. 5
In Phippen, Plaintiffs-Appellants offered Ness as an expert only after the 6
district court’s exclusion of Baccarelli, Hollander, Pearson, Cabrera, and Louie. 7
With the admission of expert testimony from Baccarelli, Hollander, and Pearson, 8
or for other reasons discussed below, it may be that Plaintiffs-Appellants would 9
no longer seek to offer Ness’s testimony. We therefore vacate the district court’s 10
judgment in Phippen, and remand for such further proceedings as the district court 11
finds appropriate, consistent with this opinion. 12
Finally, Defendants-Appellees argue that in both Rutledge and Phippen we 13
should affirm the district court’s judgment on the alternative ground that federal 14
drug labeling law preempts Plaintiffs-Appellants’ failure-to-warn claims. The 15
district court rejected that argument at the pleading stage. Here, the district court 16
did not err. Federal regulations require acetaminophen manufacturers to display 17
verbatim a general pregnancy warning, but they do not prohibit supplemental, 18
specific warnings against plausible risks. 19

-- 8 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
9
I. BACKGROUND 1
A. Acetaminophen, ADHD, and ASD 2
Plaintiffs-Appellants are parents, guardians, and children who claim that 3
they or their children developed ADHD and/or ASD due to prenatal 4
acetaminophen exposure. 5
Acetaminophen, also called paracetamol or APAP, is the active ingredient 6
in Tylenol and other over-the-counter pain relievers. It is one of the few drugs 7
indicated for use by pregnant women for pain and fever which, if left untreated, 8
can harm both the woman and fetus. It is also a drug intended for systemic 9
absorption (i.e., absorption through the blood stream). As such, when taken by 10
pregnant women, acetaminophen can cross the placental barrier and enter fetal 11
circulation. The FDA requires all such drugs to bear a general warning to pregnant 12
and nursing women advising that they consult “a health professional before use.” 13
21 C.F.R. § 201.63. But, as relevant to Plaintiffs-Appellants’ claims, the FDA does 14
not require that acetaminophen carry any warning related to ADHD and/or ASD, 15
nor do Defendants-Appellees offer such a warning. 16
ADHD and ASD are neurological developmental disorders (“NDDs”). 17
ADHD is characterized by “a persistent pattern of” inattention, hyperactivity, and 18
impulsivity “that interferes with functioning or development.” American 19
Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders (5th 20
ed., Text Revision, 2022) (“DSM”) at 70. ASD is characterized by a “persistent 21
impairment” in “social communication” and “restricted, repetitive patterns of 22
behavior, interests, or activities.” Id. at 60. Although both disorders are highly 23

-- 9 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
10
heritable, a fact that indicates some genetic influence, their precise causes are 1
unknown. Id. at 64 (ASD), 71 (ADHD). For example, while some ASD cases are 2
associated with a known genetic mutation, “[a] variety of risk factors for 3
neurodevelopmental disorders, such as advanced parental age, extreme 4
prematurity, or in utero exposures to certain drugs or teratogens like valproic acid, 5
may broadly contribute to risk of [ASD].” Id. at 64. 6
Scientists have been investigating a potential causal relationship between 7
prenatal acetaminophen use and neurodevelopmental disorders for decades but 8
no study has established such a relationship. The FDA opened a Tracked Safety 9
Issue for prenatal acetaminophen exposure in 2014 and has since conducted 10
periodic reviews of the evidence scientists have collected. In each such review, the 11
FDA has noted that while prenatal acetaminophen exposure is associated in some 12
studies with adverse neurological outcomes, study limitations and inconsistent 13
results between studies have prevented the agency from determining causality. 14
See, e.g., Abraham et al., Functional Neurobehavioral Outcomes and Urogenital 15
Outcomes Associated with Prenatal Acetaminophen Exposure, U.S. Food and Drug 16
Administration (July 15, 2022), at 33; Abraham et al., Updated Literature Review of 17
Studies that Examine the Association between Acetaminophen Exposure During 18
Pregnancy and Neurobehavioral or Urogenital Outcomes, U.S. Food and Drug 19
Administration (March 10, 2023), at 17-18. 20
In 2021, a group of thirteen authors and seventy-eight signees—consisting 21
of scientists, clinicians, and public health professionals—published a “Consensus 22
Statement” reviewing the literature on prenatal acetaminophen use and ADHD 23

-- 10 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
11
and ASD.2 The Consensus Statement concluded that “the combined weight of 1
animal and human scientific evidence is strong enough for pregnant women to be 2
cautioned by health professionals against its indiscriminate use.” Bauer et al., 3
Consensus Statement: Paracetamol Use During Pregnancy—A Call for Precautionary 4
Action, 17 Nature Revs. Endocrinology 757, 764 (2021) (“Consensus Statement”). 5
And it recommended that acetaminophen “be used by pregnant women 6
cautiously at the lowest effective dose for the shortest possible time.” Id. But it 7
notably did not conclude that the available data allowed for an inference that a 8
causal relationship exists.3 See id. The Consensus Statement built on and echoed 9
the findings of other scientists who viewed the research as potentially suggesting 10
a causal relationship. See, e.g., Olson & Liew, Fetal Programming of Mental Health by 11
Acetaminophen? Response to the SMFM Statement: Prenatal Acetaminophen Use and 12
ADHD, 16 Expert Op. on Drug Safety 1395 (2017) (summarizing research to-date 13
as “increas[ing] the probability that the association is causal”); Gou et al., 14
Association of Maternal Prenatal Acetaminophen Use with the Risk of Attention 15
Deficit/Hyperactivity Disorder in Offspring: A Meta-Analysis, 53 Austl. & N.Z. J. of 16
Psychiatry 195 (2019) (similarly concluding that recent research “lend[s] weight to 17
the hypothesis that the association is causal”). And other authorities have noted 18
2 To be clear, the “consensus” reflects the views held in common by the paper’s signatories. The
term does not suggest that the paper reflects a consensus of all experts in the relevant fields of study; as
will appear below, it most certainly does not. We use the term because it has become common in the
scientific literature as a short-hand reference for the paper in question.
3 As explained in greater detail below, “[e]pidemiologic methods cannot deductively prove
causation”; rather, “epidemiologic evidence can justify an inference, and sometimes a very strong
inference, that an agent causes a disease.” Federal Judiciary Center, Reference Manual on Scientific
Evidence (4th ed. 2025) (RMSE) at 902 n.10.

-- 11 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
12
the potential risk, including the Briggs reference guide on Drugs in Pregnancy and 1
Lactation (12th ed. 2022) which acknowledged that prior assessments of 2
acetaminophen as “not . . . caus[ing] embryo-fetal harm . . . must change because 3
of recent data.” 4
The Consensus Statement prompted replies and counterstatements from 5
other scientists and medical bodies. Those publications noted the limitations of the 6
various studies upon which the Consensus Statement relied and expressed 7
concern that the Consensus Statement could lead pregnant women experiencing 8
pain and fever to avoid acetaminophen altogether or to turn to less safe 9
alternatives. See, e.g., Alwan et al., Paracetamol Use in Pregnancy—Caution Over 10
Causal Inference from Available Data, 18 Nature Revs. Endocrinology 190 (2022) 11
(“urg[ing] against recommending [] precautionary measures for [acetaminophen] 12
use in pregnancy and against the dissemination of information based on 13
inconclusive and insufficient evidence”); O’Sullivan et al., Paracetamol Use in 14
Pregnancy—Neglecting Context Promotes Misinterpretation, 18 Nat. Rev. 15
Endocrinology 385 (2022) (expressing concern that “[t]he overarching societal 16
message that has been drawn from [the] Consensus Statement is that APAP use in 17
pregnancy is unsafe and should be restricted in both use and access”); American 18
College of Gynecologists, ACOG Response to Consensus Statement on Paracetamol Use 19
During Pregnancy (Sept. 29, 2021) (noting that “ACOG’s clinical guidance remains 20
the same and physicians should not change clinical practice until definitive 21
prospective research is done”). 22

-- 12 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
13
B. Epidemiology and Causation 1
Epidemiology is the study of the causes, incidence, and distribution of 2
diseases. RMSE at 972. Since ethical constraints render impossible many 3
experiments that might be most probative of a causal relationship (e.g., random 4
clinical trials), epidemiologists often rely instead upon observational studies. In an 5
observational study, epidemiologists “‘observe’ a group of individuals who have 6
been exposed to an agent of interest, such as . . . an industrial chemical, and 7
compare them with another group of individuals who have not been exposed.” 8
RMSE at 906. An observational study thus allows epidemiologists to determine 9
whether an association exists between an agent and a health outcome. But an 10
association “does not necessarily mean that there is a cause-effect relation” 11
between the agent and that outcome. RMSE at 921. Accordingly, “[t]o make a 12
judgment about causation,” epidemiologists consider observational studies 13
identifying an association through the lens of “several key inquiries.” RMSE at 971, 14
973. One method generally accepted by the courts for structuring that process is 15
consideration of the Bradford Hill criteria.4 See, e.g., Sarkees v. E.I. Dupont De 16
Nemours & Co., 15 F.4th 584, 591–92 (2d Cir. 2021); In re Zoloft (Setraline 17
Hydrochloride) Prods. Liab. Litig., 858 F.3d 787, 796 (3d Cir. 2017). 18
The Bradford Hill criteria are a set of factors that epidemiologists examine 19
to assess whether an observed association is causal in nature. RMSE at 973. No 20
single Bradford Hill factor is required to infer causation. Nor are the criteria “an 21
4 The Bradford Hill method takes its name from a 1965 paper by the epidemiologist Sir Austin
Bradford Hill describing the approach. See RMSE at 973.

-- 13 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
14
exhaustive []or a necessary list.” Zoloft, 858 F.3d at 796. In a Bradford Hill analysis, 1
an epidemiologist typically identifies the body of published scientific literature 2
that is relevant to their question and then analyzes the results of each of those 3
studies for the presence, or lack thereof, of each of the Bradford Hill criteria. The 4
criteria as presented in the Federal Judiciary Center’s Reference Manual on 5
Scientific Evidence5 are: 6
(1) Replication of the findings (also referred to as “consistency”): When the 7
outcomes of a study are observed “in different populations and by 8
different investigators,” this supports a causal determination. RMSE at 9
981. 10
(2) Strength: “Larger relative risks (or stronger associations using other 11
statistical measures) are often believed to be more likely to be causal than 12
smaller ones.” RMSE at 977. 13
(3) Specificity: Where an “exposure is associated only with a single disease 14
or type of disease,” this may be strong evidence in support of causality. 15
RMSE at 984. 16
(4) Dose-response relationship: If an exposure to a risk factor causes a 17
disease, then “higher exposures would generally be expected to increase 18
the incidence or severity of that disease.” RMSE at 977. Dose responses 19
may take different shapes, including a straightforward linear 20
relationship, a linear relationship after the dose exceeds a particular 21
5 Epidemiologists have formulated the Bradford Hill criteria in different ways, for example,
referring to the same criterion under a different label or consolidating multiple criteria under a single one.

-- 14 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
15
threshold, or a non-monotonic effect such as when both under-exposure 1
and over-exposure to a particular agent causes impaired outcomes. 2
RMSE at 978–81. 3
(5) Temporal relationship: Exposure to the risk factor must precede the 4
disease, because “[i]f the exposure occurs after the disease develops, it 5
cannot have caused the disease.” RMSE at 975. 6
(6) Biological plausibility: When a proposed causal relationship is consistent 7
with “current biological knowledge,” the causal inference is 8
strengthened. RMSE at 983. This is “not an easy criterion to use and 9
depends upon existing knowledge about the mechanisms by which the 10
disease develops.” RMSE at 982. “The mechanisms of some diseases are 11
understood quite well based on evidence . . . whereas other mechanism 12
explanations are merely hypothesized—although hypotheses are 13
sometimes also accepted under this factor.” RMSE at 983. 14
(7) Consistency with other relevant knowledge (also referred to as 15
“coherence”): A causal relationship should be consistent with other 16
information known about the disease. RMSE at 985. 17
(8) Cessation of exposure (also referred to as “experiment”): When 18
experimental evidence shows that “eliminating exposure reduces the 19
incidence of disease,” this supports a causal relationship. RMSE at 984. 20
In conducting this inquiry, an epidemiologist must also take care to consider “the 21
possibility that an observed association is caused by something other than the 22
exposure under study,” such as “bias and confounding.” RMSE at 984. 23

-- 15 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
16
C. Statutory and Regulatory Framework 1
“Under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq. 2
(‘FFDCA’), a new drug may not enter interstate commerce unless [the] FDA 3
determines that it is generally recognized as safe and effective (‘GRAS/E’) for the 4
particular use described in its product labeling.” NRDC v. FDA, 710 F.3d 71, 75 (2d 5
Cir. 2013). Two such pathways to a GRAS/E determination are relevant here: the 6
New Drug Application (“NDA”) process and the monograph system. 7
Under the NDA process, “a manufacturer seeking federal approval to 8
market a new drug must prove that it is safe and effective and that the proposed 9
label is accurate and adequate.” PLIVA, Inc. v. Mensing, 564 U.S. 604, 612 (2011). 10
“The FDA’s premarket approval of a new drug application includes the approval 11
of the exact text in the proposed label.” Wyeth v. Levine, 555 U.S. 555, 568 (2009). 12
After a manufacturer receives such approval, it remains charged with “ensuring 13
that its warnings remain adequate as long as the drug is on the market.” Id. at 571. 14
Hence a manufacturer may make post-approval label changes that “add or 15
strengthen a contraindication, warning, precaution, or adverse reaction” based on 16
“newly acquired information.” 21 C.F.R. § 314.70(c)(6)(iii). 17
Over-the-counter (“OTC”) drugs, however, may also be approved through 18
the monograph system. See 21 C.F.R. § 330.10; 21 U.S.C. § 355. “Under this system, 19
FDA issues a detailed regulation—a ‘monograph’—for each therapeutic class of 20
OTC drug products.” NRDC, 710 F.3d at 75. Each final monograph “establish[es] 21
conditions under which a category of OTC drugs . . . are generally recognized as 22
safe and effective and not misbranded.” 21 C.F.R. § 330.10(a)(9). A final 23

-- 16 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
17
monograph “may include any conditions relating to active ingredients, labeling 1
indications, warnings and adequate directions for use . . . necessary and 2
appropriate for the safety and effectiveness of drugs covered by the monograph,” 3
id. § 330.10(a)(5)(i), but need not dictate the full label that manufacturers must 4
apply to a product marketed under it. Moreover, manufacturers marketing a 5
specific product under the monograph “are not required to submit labeling to the 6
agency for preapproval.” Over-The-Counter Human Drugs; Labeling 7
Requirements, 64 Fed. Reg. 13254, 13271 (Mar. 17, 1999). 8
Over-the-counter acetaminophen products are marketed pursuant to the 9
monograph for Internal Analgesic, Antipyretic, and Antirheumatic Drug Products 10
(“IAAA”). See U.S. Food and Drug Administration, Over-the Counter (OTC) 11
Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug 12
Products for Over-the Counter Human Use (Oct. 14, 2022).6 The IAAA monograph 13
sets forth various labeling requirements. For example, acetaminophen labels must 14
specify only the indications for use established in the monograph. The monograph 15
does not, however, expressly prohibit additional warnings not specified therein. 16
Whether approved through the NDA or monograph system, OTC drugs 17
that are intended for systemic absorption must also contain a general pregnancy 18
and breast-feeding warning. 21 C.F.R. § 201.63 (“Pregnancy Warning 19
6 While the IAAA monograph was not finalized until 2022, it was first proposed as a tentative final
monograph in 1988, during which time it had the status of a proposed rule. See Internal Analgesic,
Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Tentative Final
Monograph, 53 Fed. Reg. 46204 (Nov. 16, 1988).

-- 17 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
18
Regulation”). Acetaminophen is one such drug. The Pregnancy Warning 1
Regulation states: 2
The labeling for all over-the-counter (OTC) drug products that are 3
intended for systemic absorption, unless specifically exempted, shall 4
contain a general warning under the heading “Warning” (or 5
“Warnings” if it appears with additional warning statements) as 6
follows: “If pregnant or breast-feeding, ask a health professional 7
before use.” [first four words of this statement in bold type] In 8
addition to the written warning, a symbol that conveys the intent of 9
the warning may be used in labeling. 10
Id. § 201.63(a) (bracketed text in original). Because the warning language identified 11
in the Pregnancy Warning Regulation is “established and identified by quotation 12
marks,” a separate regulation, the Exact Language Regulation, requires that the 13
warning appear in the “exact language” specified. Id. § 330.1(c)(2). The Pregnancy 14
Warning Regulation further provides, however, that 15
[w]here a specific warning relating to use during pregnancy or while 16
nursing has been established for a particular drug product in [an 17
NDA] or for a product covered by an OTC drug final monograph 18
[then such] specific warning shall be used in place of the warning in 19
paragraph (a) of this section [“If pregnant or breast-feeding, ask a 20
health professional before use”], unless otherwise stated in the NDA 21
or in the final OTC drug monograph. 22
Id. § 201.63(b). 23
D. Procedural Background 24
Several months after publication of the Consensus Statement that suggested 25
possible links between acetaminophen and ADHD and ASD, Plaintiffs-Appellants 26
began to file suits against the manufacturers and retailers of acetaminophen, 27

-- 18 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
19
alleging that prenatal exposure to the drug caused them or their children to 1
develop ADHD and/or ASD. Those cases were consolidated and transferred to the 2
Southern District of New York by the Judicial Panel on Multidistrict Litigation 3
pursuant to 28 U.S.C. § 1407. 4
1. Preemption Defense 5
Two Defendants-Appellees—Walmart, Inc. and Johnson & Johnson 6
Consumer Inc.—moved to dismiss three failure-to-warn actions on the ground 7
that federal law preempted the addition of ADHD and/or ASD warnings to 8
pregnant women on acetaminophen labels. The district court denied those 9
motions in separate decisions, concluding that while federal law required 10
acetaminophen manufacturers to display a general pregnancy warning, that 11
requirement did not preclude manufacturers from including an additional 12
warning specific to the risk of ADHD and/or ASD. In re Acetaminophen—ASD- 13
ADHD Prods. Liab. Litig., No. 22-md-3043, 2022 WL 17348351 (S.D.N.Y. Nov. 14, 14
2022); In re Acetaminophen—ASD-ADHD Prods. Liab. Litig., No. 22-md-3043, 2023 15
WL 3026412 (S.D.N.Y. Apr. 20, 2023). 16
2. Motions to Exclude Expert Testimony under Rule 702 and for Summary 17
Judgment 18
Following consolidation, the parties agreed first to conduct discovery 19
related to general causation (i.e., whether a causal relationship generally exists 20
between prenatal acetaminophen exposure and ADHD and ASD) and, then, if 21
Plaintiffs-Appellants’ experts survived Rule 702 motions, to proceed with the 22
remainder of discovery, including specific causation (i.e., whether a particular 23

-- 19 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
20
plaintiff developed ADHD and/or ASD because of prenatal acetaminophen 1
exposure). While Plaintiffs-Appellants bring their claims under the tort law of 2
various states, there is no dispute that “all fifty states require some evidence of 3
general causation in products liability cases involving complex products liability 4
(or medical) issues.” In re Mirena IUS Levonorgestrel-Related Prods. Liab. Litig. (No. 5
II), 982 F.3d 113, 124 (2d Cir. 2020) (internal quotation marks omitted). Plaintiffs- 6
Appellants produced five experts to opine on general causation. 7
Dr. Baccarelli is an epidemiologist and physician, an elected member of the 8
National Academy of Medicine, and dean of the Harvard T.H. Chan School of 9
Public Health. App’x 5417. He identified and analyzed the peer-reviewed 10
literature on prenatal acetaminophen exposure, then applied two epidemiological 11
methodologies—the Bradford Hill criteria and the Navigation Guide7—to 12
synthesize that evidence. Under each methodology, Baccarelli concluded that the 13
evidence supports a finding of causality. 14
Dr. Hollander is a psychiatrist and professor at the Albert Einstein College 15
of Medicine. He opined as to the interconnectedness of neurodevelopmental 16
disorders like ADHD and ASD, explaining that it is appropriate for scientists to 17
consider the two outcomes together, as well as to consider studies with 18
symptomatic endpoints, when assessing whether a causal relationship exists 19
7 The Navigation Guide is a method distinct from the Bradford Hill analysis. According to
Baccarelli, the Navigation Guide is used “to more readily evaluate causal relationships for toxic and
environmental harms.” App’x 1745. It involves the “systematic rating and review of” individualized
studies addressing a potential causal relationship “for bias, strength of evidence, and other indicia of study
quality.” Id.

-- 20 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
21
between acetaminophen and ADHD and ASD. App’x 2475. Plaintiffs-Appellants 1
offered Hollander’s testimony as support for Baccarelli’s Bradford Hill analysis, 2
which considered ADHD and ASD together, and for Baccarelli’s decision to 3
consider studies that utilized symptomatic endpoints, in addition to those that 4
relied upon ADHD and/or ASD as diagnostic outcomes. In his rebuttal report, 5
Hollander also provided his own Bradford Hill analysis. 6
Dr. Pearson is a toxicologist at Columbia University. He specializes in 7
preclinical research relating to neurodevelopmental disorders.8 Pearson’s report 8
identified and explained the biological mechanisms by which acetaminophen 9
exposure could cause ADHD and ASD based on the preclinical literature. App’x 10
2021. 11
Dr. Cabrera is a teratologist and geneticist at Baylor College of Medicine. 12
Teratology is the study of “abnormalities, malformations, and developmental 13
disorders that occur during prenatal development.” App’x 2207. Cabrera 14
reviewed the available literature and used two established methodologies— 15
weight-of-the-evidence9 and the Bradford Hill criteria—to conclude that 16
acetaminophen can cause ADHD and ASD. He also asserted the biological 17
mechanisms through which acetaminophen exposure can be a cause of ADHD and 18
8 Preclinical studies involve animal and other non-human testing.
9 As its name suggests, under the weight-of-the-evidence approach, an epidemiologist synthesizes
a review of the available scientific literature—including “clinical observations, case reports,
epidemiological and animal studies, toxicological experiments, [and] exposure data,” alongside “the
internal and external validity of th[at] data”—to arrive at an opinion on causation. App’x 2216 n.4.

-- 21 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
22
ASD by affecting neurodevelopment, using the Adverse Outcome Pathway 1
framework. 2
Dr. Louie is a professor of clinical pharmacy at the University of Southern 3
California. He reviewed the available literature and opined on plausible biological 4
mechanisms through which acetaminophen can cause ADHD and ASD, and the 5
dose and duration at which such effects could take place. He opined that the risk 6
of ADHD and ASD increases when acetaminophen is taken for at least 28 7
cumulative days during pregnancy. App’x 2737. 8
The Defendants-Appellees called six experts, only one of whom, Dr. 9
Stephen Faraone, is directly relevant to this appeal. Faraone is a professor of 10
psychiatry and neuroscience at the State University of New York Upstate Medical 11
University. In 2021, he coordinated publication of a separate consensus statement 12
that compiled “findings with [a] strong evidence base” regarding ADHD. See 13
Faraone et al., The World Federation of ADHD International Consensus Statement: 208 14
Evidence-Based Conclusions about the Disorder, 128 Neuroscience & Biobehavioral 15
Revs. 789 (2021). One finding recognized by that paper was a correlation between 16
prenatal acetaminophen use and ADHD in children. See id. at 795. In this case, 17
however, Faraone testified for the Defendants-Appellees that the scientific 18
literature does not support a causal inference between prenatal acetaminophen 19
and ADHD. 20
Following presentation of the expert reports, rebuttal reports, and expert 21
depositions, the parties each submitted Rule 702 motions. After oral argument, the 22
district court granted Defendants-Appellees’ Rule 702 motion in its entirety, 23

-- 22 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
23
excluding the testimony of Baccarelli, Hollander, Pearson, Cabrera, and Louie, and 1
denied Plaintiffs-Appellants’ Rule 702 motion as moot. The district court reasoned 2
that the testimony of each expert did not reflect a reliable application of 3
epidemiological methodologies to the question at hand, and granted summary 4
judgment to Defendant-Appellees in approximately 550 cases in the MDL. 5
Plaintiffs-Appellants appealed that decision in Rutledge. 6
A separate group of Plaintiffs-Appellants who had filed their claims after 7
the district court issued its initial Rule 702 decision subsequently sought to 8
introduce their own expert to testify on general causation for acetaminophen and 9
ADHD only. That expert, Dr. Ness, is an epidemiologist who previously served as 10
dean of the University of Texas School of Public Health and as a professor in public 11
health at the University of Texas Houston until her retirement. She conducted a 12
Bradford Hill analysis that was responsive to the district court’s analysis and 13
exclusion of the previous five experts, and testified that there is a causal 14
relationship between prenatal acetaminophen exposure and ADHD. 15
Defendants-Appellees filed a Rule 702 motion to exclude Ness. The district 16
court granted the motion, holding that Ness’s testimony did not appropriately 17
account for genetic confounding and improperly cherry-picked among studies. 18
Like their predecessors, this subset of Plaintiffs-Appellants was ordered to show 19
cause why final judgment should not be entered. They contested the exclusion of 20
Ness and argued, in the alternative, that summary judgment was not appropriate 21
because Faraone’s earlier statements in support of a causal connection between 22
acetaminophen and ADHD could allow a reasonable jury to find in Plaintiffs- 23

-- 23 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
24
Appellants’ favor on the issue of general causation. The district court granted 1
summary judgment for Defendants-Appellees, continuing to exclude Ness and 2
explaining that “even if each [Faraone] statement were admissible, the statements 3
would not constitute reliable evidence of general causation in support of the 4
plaintiffs’ theory.” In re Acetaminophen – ASD-ADHD Prods. Liab. Litig., 2024 WL 5
3874183, at *4 n.6 (S.D.N.Y. Aug. 20, 2024). That judgment is the basis of the appeal 6
in Phippen. 7
Plaintiffs-Appellants now bring these tandem appeals challenging, in 8
Rutledge, the district court’s exclusion of the five general causation experts for 9
ADHD and ASD (Baccarelli, Hollander, Pearson, Cabrera, and Louie), and in 10
Phippen, one general causation expert as to ADHD (Ness). The Phippen Plaintiffs- 11
Appellants further argue in the alternative that, even if all experts remain 12
excluded, summary judgment was not appropriate because a reasonable jury 13
could rely on Faraone’s statements to find for Plaintiffs-Appellants. Defendants- 14
Appellees contend that these experts were properly excluded and that, even if they 15
weren’t, we should affirm the district court’s judgments because the FDA’s 16
regulations preempt any state law that would require Defendants-Appellees to 17
supplement the FDA’s mandated pregnancy warning on their products. 18
II. Discussion 19
A. Rule 702 Legal Framework 20
The admissibility of expert scientific testimony is governed by the Federal 21
Rules of Evidence. Rule 702 provides that: 22

-- 24 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
25
[a] witness who is qualified as an expert by knowledge, skill, 1
experience, training, or education may testify . . . if the proponent 2
demonstrates to the court that it is more likely than not that: (a) the 3
expert’s scientific, technical, or other specialized knowledge will help 4
the trier of fact to understand the evidence or to determine a fact in 5
issue; (b) the testimony is based on sufficient facts or data; (c) the 6
testimony is the product of reliable principles and methods; and (d) 7
the expert’s opinion reflects a reliable application of the principles 8
and methods to the facts of the case. 9
See also Daubert v. Merrell Dow Pharms., 509 U.S. 579, 598 (1993). This standard 10
requires district courts to look carefully at the qualifications and methodology of 11
each expert. 12
1. Qualifications 13
“To determine whether a witness qualifies as an expert, courts compare the 14
area in which the witness has superior knowledge, education, experience, or skill 15
with the subject matter of the proffered testimony.” United States v. Tin Yat Chin, 16
371 F.3d 31, 40 (2d Cir. 2004). “Experts need not conduct studies of their own in 17
order to opine on a topic; a review of other studies and scientific literature can be 18
enough to qualify experts to testify and to make that proposed testimony reliable.” 19
In re Mirena IUD Prods. Liab. Litig., 169 F. Supp. 3d 396, 412 (S.D.N.Y. Mar. 8, 2016), 20
citing McCullock v. H.B. Fuller Co., 61 F.3d 1038, 1042–43 (2d Cir. 1995). 21
2. Reliability 22
In addition to confirming that experts are qualified to offer testimony, Rule 23
702 charges district courts with the “task of ensuring that an expert’s testimony 24
both rests on a reliable foundation and is relevant to the task at hand.” Daubert, 25
509 U.S. at 597. To determine reliability, the district court may consider whether 26

-- 25 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
26
the expert’s theory or technique can and has been tested; whether it has been 1
subjected to peer review and publication; whether it has a known error rate or 2
standards to control its operation; and its general acceptance in the relevant 3
scientific community. Id. at 593–94. The objective of this gatekeeping requirement 4
is “to make certain that an expert, whether basing testimony upon professional 5
studies or personal experience, employs in the courtroom the same level of 6
intellectual rigor that characterizes the practice of an expert in the relevant field.” 7
Kumho Tire Co. v. Carmichael, 526 U.S. 137, 152 (1999). “In deciding whether a[n] . . . 8
expert’s analysis is []reliable, the district court should undertake a rigorous 9
examination of the facts on which the expert relies, the method by which the expert 10
draws an opinion from those facts, and how the expert applies the facts and 11
methods to the case at hand.” Amorgianos v. Nat’l R.R. Passenger Corp., 303 F.3d 256, 12
267 (2d Cir. 2002). 13
While the focus of the court’s Daubert inquiry should be “on principles and 14
methodology, not on the conclusions that they generate,” Daubert, 509 U.S. at 595, 15
“conclusions and methodology are not entirely distinct from one another,” Gen. 16
Elec. Co. v. Joiner, 522 U.S. 136, 146 (1997). Accordingly, “nothing in either Daubert 17
or the Federal Rules of Evidence requires a district court to admit opinion evidence 18
that is connected to existing data only by the ipse dixit of the expert.” Id. 19
Consequently, “when an expert opinion is based on data, a methodology, or 20
studies that are simply inadequate to support the conclusions reached, Daubert 21
and Rule 702 mandate the exclusion of that unreliable opinion testimony.” 22
Ruggiero v. Warner-Lambert Co., 424 F.3d 249, 255 (2d Cir. 2005), quoting 23
Amorgianos, 303 F.3d at 266. 24

-- 26 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
27
As the Rules Committee has explained, “[i]t will often occur that experts 1
come to different conclusions based on contested sets of facts. Where that is so the 2
[rule] does not necessarily require exclusion of either side’s experts.” Fed. R. Civ. 3
P. 702 committee note to 2023 amendment. That is because a party “do[es] not have 4
to demonstrate to the judge by a preponderance of the evidence that the 5
assessments of their experts are correct, they only have to demonstrate by a 6
preponderance of the evidence that their opinions are reliable.” Id. (internal 7
quotation marks omitted). “The evidentiary standard of reliability is lower than 8
the merits standard of correctness.” Id. (internal quotation marks omitted). 9
3. Standard of Review 10
“We review a district court’s determination to admit or exclude expert 11
testimony under Daubert for abuse of discretion.” Amorgianos, 303 F.3d at 264. A 12
decision to admit or exclude expert scientific testimony is not an abuse of 13
discretion unless it is “manifestly erroneous.” In re Mirena (No. II), 982 F.3d at 122 14
(2d Cir. 2020) (internal quotation marks omitted). 15
B. Rule 702 Application 16
As to the first prong of the Rule 702 analysis in Rutledge, we agree with the 17
district court that “[e]ach of the parties’ experts is eminently qualified.” 707 F. 18
Supp. 3d at 317. 19
On the second prong, while the district court’s review of the expert 20
testimony at issue in this case was thorough and well-documented, we conclude 21
that, in the case of Baccarelli, Hollander, and Pearson, the court went beyond its 22
proper role as gatekeeper by excluding experts whose testimony was consistent 23

-- 27 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
28
with the methodologies actually employed in their field; by substituting its own 1
understanding of various epidemiological criteria for that of the expert scientists; 2
and by faulting the scientists for reaching particular conclusions where there is 3
disagreement in the scientific community over the proper interpretation of the 4
body of evidence. What follows is a non-exhaustive list of the instances in which 5
we hold the district court to have been in error. These instances, we find, are 6
sufficient to vacate the district court’s opinion as to Baccarelli, Hollander, and 7
Pearson and to hold their testimony to be admissible. It bears repeating that this is 8
not to say that we deem the opinions of those experts correct on the issue of 9
causation, we hold only that the district court erred in deeming their testimonies 10
unreliable and therefore not worthy of consideration by a jury. And because we 11
find that the district court erred in its assessment in Rutledge, we need not reach 12
the district court’s assessment of Ness in Phippen. 13
As will be made clear, our analysis primarily focuses on Baccarelli’s opinion, 14
which also sits front and center in the parties' briefing and the district court's 15
analysis. That opinion is the broadest in scope and supplies the foundation for 16
Plaintiffs-Appellants’ assertion of a causal relationship between prenatal exposure 17
to acetaminophen and ASD and ADHD. The other experts' opinions, while also 18
noteworthy, serve to support and corroborate aspects of Baccarelli's analysis. 19
1. Baccarelli 20
a. Transdiagnostic Bradford Hill analysis 21
The district court first rejected Baccarelli’s testimony because of how he 22
structured his Bradford Hill analysis. Baccarelli performed a single Bradford Hill 23

-- 28 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
29
analysis to examine the effect of prenatal acetaminophen on ADHD, ASD, and 1
neurodevelopmental symptoms consistent with those disorders. The parties and 2
the district court have referred to this as a “multiple-outcomes” or 3
“transdiagnostic” approach. As inputs to that analysis, Baccarelli considered peer- 4
reviewed studies that used both diagnostic and non-diagnostic endpoints. 5
Diagnostic endpoint studies examine populations that have been diagnosed with 6
the condition of interest (e.g., ADHD and/or ASD), whereas non-diagnostic 7
endpoint studies use outcomes such as symptoms or closely related conditions 8
(e.g., neurodevelopmental deficits associated with ADHD and/or ASD). In other 9
words, he performed a single Bradford Hill analysis on both ADHD and ASD 10
together and used studies that examined both symptomatic and diagnostic 11
outcomes. 12
Baccarelli explained this methodological choice in his report: “[D]ifferent 13
NDDs often have shared/overlapping symptomology as well as shared biological 14
pathways or causes . . . . Therefore, in assessing the association between 15
acetaminophen exposure in utero and neurodevelopmental disorders like ASD 16
and ADHD, it is important to consider not just the clinical diagnoses but also the 17
neurodevelopmental outcomes, including the symptoms.” App’x 1778. He 18
acknowledged in his rebuttal report that while “studies showing an association 19
between prenatal [acetaminophen] exposure and clinical diagnoses of ADHD and 20
ASD provide particularly powerful evidence of a causal relationship,” that “in no 21
way suggests that researchers should blind themselves to the results from studies 22
using other endpoints that are obviously relevant to the question at hand.” App’x 23
2892. 24

-- 29 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
30
The district court held that this methodological choice was inappropriate 1
because, while ADHD and ASD share some symptoms, “the diagnostic criteria of 2
the two disorders are undeniably distinct.” 707 F. Supp. 3d at 340. And the district 3
court further concluded that the focus on symptomatic outcomes rendered 4
Baccarelli’s testimony irrelevant because “this litigation is brought to obtain 5
recovery on behalf of those who have been diagnosed with ASD or ADHD, not on 6
behalf of anyone with, for example, a deficit in communication or self-regulation.” 7
Id. at 339. The district court also asserted that the multiple-outcomes approach 8
“obscured limitations in the scientific literature,” such that “[i]f the studies for 9
either ASD or ADHD were subjected to their own individual Bradford Hill 10
analysis, it would be easier to discern whether there was actual support for a 11
finding that prenatal exposure to acetaminophen causes either ASD or ADHD.” 12
Id. 13
That ruling was erroneous because it penalized Baccarelli for using a 14
methodology that epidemiologists routinely use—in other words, for testimony 15
that embodies “the same level of intellectual rigor that characterizes the practice 16
of an expert in the relevant field.” Kumho Tire Co., 526 U.S. at 152. 17
Scientists have conducted multiple-outcome Bradford Hill analyses 18
examining, for example, the relationship between air pollution, mental diseases, 19
and mortality; between e-cigarettes and various types of oral cancers; and between 20
psychological factors and irritable bowel disease (encompassing Crohn’s disease 21

-- 30 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
31
and ulcerative colitis).10 Moreover, other scientists have, independently, examined 1
the Bradford Hill criteria for ADHD and ASD together. See Alemany et al., Prenatal 2
and Postnatal Exposure to Acetaminophen in Relation to Autism Spectrum and Attention- 3
Deficit and Hyperactive Symptoms in Childhood, 36 Euro. J. Epidemiology 993, 1000 4
(2021). And the FDA has likewise considered the relationship between “in utero 5
[acetaminophen] exposure and neurobehavioral and urogenital outcomes.” 6
Abraham 2023, at 3. 7
8
9
10
App’x 6610, 6613. 11
Baccarelli’s use of studies that examine non-diagnostic endpoints, in 12
addition to those that used diagnostic ones, likewise did not render his testimony 13
unreliable. Other scientists not involved in this litigation studying the connection 14
between prenatal acetaminophen exposure and ADHD and ASD have routinely 15
utilized symptomatic endpoints alone or in combination with diagnostic ones— 16
10 See, e.g., John P.A. Ioannidis, Air Pollution as Cause of Mental Disease: Appraisal of the Evidence, 17 PLOS
Biology (2019) (evaluating the connection between “air pollution” and “mental disease,” including
depression, bipolar disorder, schizophrenia, and personality disorder); Raj et al., Reviewing the Oral
Carcinogenic Potential of E-Cigarettes Using the Bradford Hill Criteria of Causation, 9 Translational Cancer
Rsch. 3142 (2020) (evaluating “e-cigarettes” and “oral cancer”); Schoultz et al., Assessment of Causal Link
Between Psychological Factors and Symptom Exacerbation in Inflammatory Bowel Disease: A Systematic Review
Utilising Bradford Hill Criteria and Meta-Analysis of Prospective Cohort Studies, 9 Systematic Revs. (2020)
(evaluating “irritable bowel disease” and “psychological stress,” which encompassed a “variety of
minor to major psychological factors”).

-- 31 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
32
several of which Baccarelli cites. See, e.g., App’x 1840 (citing Avella-Garcia 2016,11 1
which measured “autism spectrum symptoms” and “inattention and 2
hyperactivity/impulsivity symptoms”); App’x 1834 (citing Masarwa 2018,12 a 3
meta-analysis that discussed studies with both diagnostic and symptomatic 4
endpoints). At least one of Defendants-Appellees’ experts also discussed 5
symptom-endpoint studies in a textbook chapter. See App’x 4836 (Dr. Alexander 6
Kolevzon citing Masarwa 2018). 7
. See App’x 8
6652 ( ); App’x 6655 ( 9
); App’x 6649 ( 10
). 11
12
13
. App’x 6654. 14
We do not mean to suggest that all Bradford Hill analyses that 15
simultaneously examine multiple outcomes, or that use symptomatic as well as 16
diagnostic endpoints, are reliable and admissible under Rule 702. We can imagine, 17
11
.
12
.
13
.
14
.

-- 32 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
33
for example, conditions which are sufficiently distinct so that a single, joint, 1
analysis could not be performed in a reliable manner. There may well be 2
conditions for which symptoms alone, without a diagnosis, may well be of little 3
practical use to scientists looking to understand what may cause a disease. But that 4
is not the case here, where the technique at issue has “attract[ed]” “[w]idespread 5
acceptance” in the relevant scientific “community,” Daubert, 509 U.S. at 594 6
(internal quotation marks omitted), 7
.15 8
To restate the obvious, we do not conclude that we think the structure 9
Baccarelli employed for his Bradford Hill analysis is the best one, nor do we have 10
any prediction, one way or another, about whether a jury will find it persuasive. 11
Those are not the issues before us. The single, multiple-outcomes analysis may 12
well prove unconvincing to a jury for precisely the reasons that the district court 13
identifies, but that does not render the expert opinion excludable for the purposes 14
of Rule 702. 15
15 The district court also said the multiple-outcomes analysis should be excluded because it “obscure[s]
limitations in the scientific literature” such that, if the analysis were focused on a single disorder, the
reliability of such testimony would be easier to determine. 707 F. Supp. 3d at 339. But the concern that
the multiple-outcomes analysis prevents a factfinder from disentangling the studies assessing ASD from
those assessing ADHD is undermined by the district court’s own opinion doing exactly that. While it
might have been easier to sort through the Rule 702 motions if Baccarelli’s Bradford Hill analysis had
treated ADHD and ASD separately, the district court still ably sifted through the various studies, opined
on the limitations in the literature regarding ASD, and thoroughly analyzed the issue of genetic
confounding.

-- 33 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
34
b. Bradford Hill Factors 1
The district court next held that, even if it were methodologically reliable 2
for Baccarelli to assess multiple outcomes and to rely on studies that used both 3
diagnostic and symptomatic endpoints, Baccarelli applied that method in an 4
unreliable manner. We find that the court, in so holding, improperly (i) substituted 5
its own definitions of certain Bradford Hill factors for those of other 6
epidemiologists, and (ii) penalized Baccarelli for drawing plausible conclusions 7
well within “the range where experts might reasonably differ.” Kumho Tire, 526 8
U.S. at 152. What follows is a non-exhaustive discussion of instances in which the 9
district court overstepped its gatekeeping function. 10
i. The definition of individual factors 11
The district court’s discussion of Baccarelli’s testimony on dose response, 12
biological plausibility, strength, and specificity illustrate the first point. On dose 13
response, the district court faulted Baccarelli for failing to grapple with “a key 14
issue in the underlying studies,” which was that “none were able to record the 15
actual dosages taken by pregnant women.” 707 F. Supp. 3d at 350 (emphasis in 16
original). But the district court cited no scientific authority for the proposition that 17
dose-response analysis requires data on the precise doses that study participants 18
ingested. And multiple meta-analyses of the same literature that Baccarelli 19
analyzed made dose-response judgments similar to his. See, e.g., Alemany 2021 20
(recognizing that multiple prior studies found a dose-response relationship); Ricci 21

-- 34 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
35
202316 (finding that the association between acetaminophen exposure and ADHD 1
was strongest in children with the highest duration of exposure, “suggesting a 2
dose-response effect”). Indeed, the district court noted that “[t]he closest 3
approximation to dose in the underlying studies is days of use.” 707 F. Supp. at 350 4
(emphasis added). In other words, the district court faulted Baccarelli for 5
analyzing acetaminophen dose response in exactly the manner used by scientists 6
in his field, utilizing the best available proxy for data that would rarely if ever be 7
available in observational studies, and that for ethical reasons could not be 8
collected by a controlled experimental study. 9
On biological plausibility, the district court discredited Baccarelli’s 10
testimony because “[a]t present, the precise physiological process or processes by 11
which these conditions, or NDDs more generally, develop are unknown.” Id. It 12
found that because “[s]cientists have at best developed hypotheses” as to the 13
biological mechanisms by which acetaminophen causes ADHD and ASD, 14
“Baccarelli’s conclusion that this factor is satisfied . . . fail[s] to reflect a reliable 15
application of scientific principles.” Id. 16
There is no doubt that any causal relationship between acetaminophen and 17
ADHD and ASD is quite uncertain. But the Bradford Hill methodology does not 18
require certainty regarding the mechanisms by which exposure causes the 19
condition of interest—indeed, if such proof were available, there would be no need 20
for the multi-factor epidemiological inquiry in the first place. The Bradford Hill 21
16 Ricci et al., In Utero Acetaminophen Exposure and Child Neurodevelopmental Outcomes: Systematic
Review and Meta-Analysis, 37 Paediatric Perinatal Epidemiology 473 (2023).

-- 35 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
36
methodology asks no more than whether there is some such “biologically plausible 1
mechanism.” App’x 1906 (emphasis added).17 In other words, it “asks whether the 2
hypothesized causal link is credible in light of what is known from science and 3
medicine” about the alleged toxin and its biological effects. Milward v. Acuity 4
Specialty Prods. Grp., Inc., 639 F.3d 11, 25 (1st Cir. 2011). And Baccarelli’s approach 5
to biological plausibility, in this respect, finds support in the practices of other 6
epidemiologists outside the courtroom, in assessing both whether acetaminophen 7
exposure causes ADHD and ASD,18 and in investigations into the potential causes 8
of other conditions.19 Baccarelli hence applied the biological plausibility criterion 9
with “the same level of intellectual rigor that characterizes the practice of an 10
expert” in his field. Kumho Tire Co., 526 U.S. at 152. Of course, the jury remains free 11
to consider the fact that scientists have not definitively identified a mechanism of 12
causation and to assign the weight to that fact it deems appropriate. 13
17 See also Sir Austin Bradford Hill, The Environment and Disease: Association or Causation?, 58 Proc.
Royal Soc’y Med. 295, 298 (1965) (“It will be helpful if the causation we suspect is biologically plausible.
But this is a feature I am convinced we cannot demand. What is biologically plausible depends upon the
biological knowledge of the day.”).
18 See, e.g., Gustavson et al., Acetaminophen Use During Pregnancy and Offspring Attention Deficit
Hyperactivity Disorder -- A Longitudinal Sibling Control Study, 1 JCPP Advances at 2 (2021) (“Biologically
plausible mechanisms for effect on fetal neurodevelopment include oxidative stress and neurotoxicity.”);
Chen et al., Prenatal Exposure to Acetaminophen and the Risk of Attention-Deficit/Hyperactivity Disorder: A
Nationwide Study in Taiwan, 80 J. Clin. Psychiatry at 5 (2019) (identifying “[s]everal biologically plausible
contentions,” including that “acetaminophen may alter the intrauterine immune system and increase the
predisposition for oxidative stress and inflammation”).
19 See, e.g., Bello et al., Does Human Papillomavirus Play a Causative Role in Prostate Cancer? A
Systematic Review Using Bradford Hill’s Criteria, 15 Cancers at 7 (2023) (finding biological plausibility
satisfied in part based on “the oncogenic role of HPV in other types of cancers”); Davidson & Smith, The
Bradford Hill Criteria and Zinc-Induced Anosmia; A Causality Analysis, 136(7) Archives of Otolaryngology –
Head Neck Surgery 673, 675 (2010) (concluding that biological plausibility is satisfied based on
experimental animal evidence showing that zinc exposure causes temporary anosmia).

-- 36 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
37
In its analysis of strength, the district court first noted that most of the 1
studies dealing with ADHD and/or ASD show a risk ratio of between 1.0 and 2.0,20 2
which is lower than the ratios present in other cases in this Circuit. See, e.g., In re 3
Mirena IUS Levonorgestrel-Related Prods. Liab. Litig. (No. II), 341 F. Supp. 3d 213, 243 4
(S.D.N.Y. 2018), aff’d 982 F.3d 113 (2d Cir. 2020) (risk ratios of 3.90 and 7.69); 5
Daniels-Feasel v. Forest Pharmaceuticals, Inc., No. 17-cv-4188, 2021 WL 4037820, at 6
*8 (S.D.N.Y. Sept. 3, 2021), aff’d No. 22-146, 2023 WL 4837521 (2d Cir. 2023) (risk 7
ratio of 2.2). The district court next found that Baccarelli improperly found support 8
for the strength criterion in meta-studies that synthesized underlying studies with 9
varying levels of statistical significance. For example, the district court noted that 10
while the Alemany 2021 meta-study found an overall risk ratio of 1.19 for ASD, 11
only one of the six underlying studies it considered found a statistically significant 12
risk ratio. The court concluded from this that it was “misleading to characterize 13
the highly heterogenous body of literature as reporting consistent statistically 14
significant associations.” 707 F. Supp. 3d at 347. 15
But Baccarelli explained that while the risk ratio reported by each study is 16
relatively low, ranging from 1.0 to 2.0, there is “no general rule for how large an 17
association needs to be” to satisfy this criterion. App’x 1901; see also Hardeman v. 18
Monsanto Co., 997 F.3d 941, 966 (9th Cir. 2021) (rejecting contention that plaintiff’s 19
experts were wrongfully admitted because they failed “to present a study with an 20
adjusted odds ratio above 2.0” and recognizing that “a hardline increase in a risk 21
20 A risk ratio refers to “[t]he ratio of the risk of disease or death among people exposed to an agent
to the risk among the unexposed.” RMSE at 1019. For example, a risk ratio of 2.0 means that “the disease
occurs twice as frequently among” people exposed to the agent as compared to those not exposed. Id.

-- 37 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
38
statistic, or even an adjusted odds ratio above 2.0, is [not] necessary for finding a 1
strong association”), abrogated on other grounds by Monsanto Co. v. Durnell, No. 24- 2
1068, 2026 WL 1825691 (June 25, 2026). He further noted that the risk ratio for 3
ADHD and ASD is stronger than others that epidemiologists have generally 4
agreed plausibly reflect causal effects. Among these are the links between air 5
pollution and mortality, between smoking and heart disease, and between 6
secondhand smoke and lung cancer. App’x 1901. In other words, Baccarelli 7
demonstrated that it is not inconsistent with epidemiological practice to conclude 8
that the strength condition is satisfied with a risk ratio between 1.0 and 2.0. 9
Moreover, Baccarelli correctly stated that it is not inconsistent with 10
epidemiological practice to cite a meta-study—the express purpose of which is to 11
“provide a more precise estimate of the true effect size of an association, by 12
synthesizing data from multiple studies and reducing random error”—in support 13
of a causal conclusion, even if the individual cohorts in that meta-analysis do not 14
produce statistically significant results. App’x 1807. 15
Baccarelli additionally testified that the strength criterion is further 16
supported because the magnitude of risk measured in many of the studies he 17
assessed may have been dampened due to their reliance on maternal self-reporting 18
of acetaminophen, which likely underestimated the true exposure. App’x 1901. In 19
support of this conclusion, he cites Baker 202021, a study that directly measured 20
the presence of acetaminophen in infant meconium (an infant’s first feces that can 21
21 Baker et al., Association of Prenatal Acetaminophen Exposure Measured in Meconium with Risk of
Attention-Deficit/Hyperactivity Disorder Mediated by Frontoparietal Network Brain Connectivity, 174(11) JAMA
Pediatrics 1073 (2020).

-- 38 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
39
reflect prenatal exposure) and which reported a risk ratio of 2.43. The district court 1
criticized Baccarelli for relying on Baker 2020, despite recognizing it as “well- 2
regarded,” because that study had a “wide confidence interval” (spanning 1.41 to 3
4.21), which the district court held “undercut[] its reliability.” 707 F. Supp. 3d at 4
348. But although the width of a confidence interval is relevant to the reliability of 5
a risk ratio estimate, that does not warrant the wholesale rejection of Baker 2020. 6
Rather, that is a fact for a factfinder to consider in assessing the persuasiveness of 7
the study. 8
Finally, on specificity, the district said that in light of the “complexity” 9
suggested by the “absence” of specificity, Baccarelli neglected to “consider 10
whether the studies upon which [he] is relying adequately considered 11
confounding effects, among other things.” 707 F. Supp. 3d at 349. That gives more 12
weight to the specificity factor than many epidemiologists do. Baccarelli explained 13
that even if the specificity criterion is not satisfied, it is considered “all but 14
irrelevant” to modern epidemiologists. App’x 1904; see also RMSE at 985 15
(describing the specificity factor as “highly debatable”); VanderWeel et al., Causal 16
Inference and Scientific Reasoning, in Lash’s Modern Epidemiology 67 (4th ed. 2020) 17
(recognizing that “many behavioral, environmental, social, and genetic risk factors 18
have been causally linked to more than one health outcome”). The district court 19
cited no authority for the proposition that, in a Bradford Hill analysis, lack of 20
specificity necessarily indicates a dubious causal analysis. Where, as here, the 21
causes of a disorder are multifactorial, lack of specificity does not weigh 22
significantly against an ultimate conclusion of plausible causality. See App’x 1904. 23

-- 39 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
40
ii. Conclusions on contested scientific questions 1
The second group of errors in the district court’s analysis of Baccarelli’s 2
Bradford Hill testimony concerns instances in which the district court arrives at a 3
definitive interpretation of a given study that reasonable scientists could interpret, 4
and indeed have interpreted, differently. The district court’s analysis of these 5
issues is couched in terms of scientific “rules” of interpretation that it decided 6
Baccarelli did not follow: first, that he engaged in cherry-picking, and second, that 7
he exceeded the limitations that authors placed upon their own studies. While 8
these court-created rules address legitimate concerns pertaining to the reliability 9
of expert testimony, the court applied them in a manner inconsistent with how 10
scientists practice. 11
Take cherry-picking. Cherry-picking occurs when an expert points to data 12
that support a particular position while ignoring or discrediting data that 13
contradict it. It is not cherry-picking for an expert to prefer one study to another 14
when he offers a coherent, scientifically plausible reason for the preference. This 15
issue is illustrated by the district court’s discussion of Baccarelli’s testimony on 16
genetic confounding (that is, whether any observed association between prenatal 17
acetaminophen and ASD and ADHD can be attributed to genetics). No one, 18
including Baccarelli, denies that genetics play a role in ADHD/ASD. But that does 19
not mean that the scientific literature has concluded that genetic confounding 20
accounts for all of the observed association. On this issue, reasonable scientists can, 21
and do, disagree. The district court characterized Baccarelli’s reasonable 22
interpretations of studies addressing genetic confounding as cherry-picking. In 23

-- 40 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
41
doing so, the district court ignored the detailed explanations Baccarelli provided 1
for his interpretations. That was error. 2
The district court first took issue with Baccarelli’s treatment of Brandlistuen 3
201322 and Gustavson 2021, two sibling-control studies designed to control for the 4
effects of genetic confounding. The two studies examined the same population 5
several years apart. Brandlistuen 2013, the earlier study, measured ADHD 6
symptoms as its endpoint, while Gustavson 2021, the later study, measured 7
ADHD diagnoses. Brandlistuen 2013 found an association that persisted even after 8
controlling for genetic confounding using a method called a “sibling-control” 9
analysis, while Gustavson 2021 did not. The district court criticized Baccarelli for 10
interpreting these studies as supporting his conclusion that genetic confounding 11
does not account for the entire association at issue, stating that he did not “explain 12
his disparate treatment of the two studies.” 707 F. Supp. 3d at 353. But Baccarelli 13
did: In his report, he explains that results from sibling-control studies are biased 14
toward the null—that is, they understate the true associations at issue—because 15
they control for both the genetic factors that directly cause the disease outcome at 16
issue, and the genetic factors by which the agent at issue may cause the disease 17
outcome. Baccarelli also noted that the authors of Gustavson 2021 acknowledged 18
this as a limitation in their analysis, and that this limitation “may lead to 19
underestimation of association estimates.” App’x 1860 (internal quotation marks 20
omitted). Moreover, Baccarelli does not overstate the value of Brandlistuen 2013 21
22 Brandlistuen et al., Prenatal Paracetamol Exposure and Child Neurodevelopment: A Sibling-Controlled
Cohort Study, 42(6) Int’l J. Epidemiology 1702 (2013).

-- 41 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
42
and Gustavson 2021 to his ultimate conclusion, saying only that “[i]t is unclear 1
whether these studies provide any meaningful evidence regarding the role of 2
unmeasured or genetic confounding.” App’x 1866. It was thus error to charge 3
Baccarelli with cherry-picking in this part of his testimony. 4
Another example of a misplaced charge of cherry-picking is the district 5
court’s treatment of Baccarelli’s testimony concerning Ystrom 201723. That study 6
used paternal acetaminophen use as a negative control meant to isolate the effect 7
of acetaminophen on ADHD from familial effects, since, as the Ystrom authors 8
hypothesized, “[i]f the association is due to unobserved familial factors (e.g., 9
genetic factors), paternal use of acetaminophen may also be associated with 10
ADHD in a way similar to maternal use of acetaminophen.”24 The authors found, 11
among other results, an association between paternal preconceptual use of 12
acetaminophen and ADHD. The district court suggested that Baccarelli’s 13
discussion of this study is not “scientifically sound” because he “speculates that 14
paternal use might have [instead] been serving as an imperfect proxy for maternal 15
use because, among other things, ‘fathers and mothers often share medications 16
and medicine cabinets.’” 707 F. Supp. 3d at 353, quoting App’x 1858. That 17
speculation, the district court decided, was another instance of Baccarelli’s 18
“dismissal of evidence that challenges his thesis.” Id. 19
23 Ystrom et al., Prenatal Exposure to Acetaminophen and Risk of ADHD, 140(5) Pediatrics 1 (2017).
24 See, e.g., Sanderson et al., Negative Control Exposure Studies in the Presence of Measurement Error:
Implications for Attempted Effect Estimate Calibration, 47(2) Int. J. Epidemiology 587 (2018) (discussing
negative control experiments).

-- 42 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
43
But the district court’s charge misrepresents the nuance with which 1
Baccarelli addressed this study. Baccarelli explained, and the authors of Ystrom 2
2017 acknowledged, that “the mechanics of the ADHD effect of paternal 3
acetaminophen use before pregnancy are unclear but . . . may be due to male 4
germ-line epigenetic effects as described in endocrine disruption effects of 5
acetaminophen on the human testis.” App’x 1858 (internal citations omitted). In 6
other words, paternal preconceptual acetaminophen use may itself also be 7
causally associated with ADHD in a manner that suggests that it should not 8
operate as a valid negative control. And although Baccarelli’s reference to shared 9
medicine cabinets may not have used the most “scientific” language, his 10
underlying point is not unreasonable. The study design used paternal 11
acetaminophen exposure as a negative control but also found that paternal use 12
was correlated with maternal use—so, as Baccarelli explains, if paternal use is 13
actually acting as a proxy for maternal use, then the association that was found 14
between paternal use and ADHD could be consistent with a causal relationship 15
between maternal use and ADHD. Baccarelli’s consideration of this study is not 16
an example of results-driven analysis of the sort that would render his testimony 17
unreliable. Again, we emphasize that we are not saying that the district court’s 18
questioning of Bacarelli’s logic is itself unreasonable; still less are we suggesting 19
that similar arguments that may be made by Defendants-Appellees’ experts 20
(which are not before us for review, and the admissibility of which has not been 21
decided by the district court) would be improper, unreliable, or “unscientific.” The 22
point is that these are arguments and counter-arguments of the sort that scientists 23
can and do make when engaging in professional academic debates about contested 24

-- 43 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
44
scientific questions. The gatekeeping role of the district court is to shield the jury 1
from testimony by even qualified experts that is outside the boundaries of 2
ordinary scientific discourse and thus constitutes “junk science.” It is not to 3
adjudicate which points in the debate are more persuasive; that is the role of the 4
jury.25 5
The second way that the district court censures Baccarelli for drawing 6
reasonable conclusions is by misapplying the rule that when an expert “relies on 7
the studies of others, he must not exceed the limitations the authors themselves 8
place on the study.” Daniels-Feasel, 2021 WL 4037820, at *4 (internal quotation 9
marks omitted). It is important that when experts use work produced by other 10
scientists, they do not paper over the limitations inherent in those studies. But the 11
district court stretches that maxim too far in the context of a Bradford Hill analysis, 12
which is a methodology for synthesizing many scientific results where no single 13
one definitively establishes or negates a causal relationship. A study that does not 14
itself prove causation, because of its own limitations, can nonetheless serve as a 15
reliable link in a chain supporting a particular Bradford Hill factor. And that study, 16
25 This understanding is fully consistent with the 2023 amendments to Rule 702. Those amendments
sought to correct the “hands-off” approach to expert testimony that the Rules Committee perceived had
been applied by many district courts. See Fed. R. Civ. P. 702 advisory committee’s note to 2023 amendment
(noting that many district courts improperly treated “critical questions of the sufficiency of an expert’s
basis, and the application of the expert’s methodology” as “questions of weight and not admissibility”).
But the principle that a district court must take a hard look at the experts’ applications of accepted methods
does not justify disregarding another principle—that the district court cannot decide a Daubert motion
based on its own judgment of an expert’s persuasiveness. Instead, the district court should strike a middle-
ground between those two principles, taking a hard look at the expert’s opinions to ensure that they are
reliable without necessarily addressing whether they are correct. We recognize that this is easier said than
done, but we trust the district courts to perform this inquiry and afford them substantial discretion in doing
so.

-- 44 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
45
in combination with other studies that address that limitation (and indeed may 1
have other deficiencies of their own), may ultimately support a conclusion that 2
points toward causation. This issue is best illustrated by the district court’s 3
treatment of the consistency and strength Bradford Hill factors allegedly 4
supporting Baccarelli’s conclusion. 5
On the issue of consistency, the district court concluded that limitations in 6
each of the studies on prenatal acetaminophen use and ASD precluded Baccarelli 7
from finding that the consistency criterion is satisfied for ASD. 707 F. Supp. 3d at 8
343–44. In doing so, however, the district court unreasonably discounted 9
Baccarelli’s explanation of why those limitations should not bar a finding of 10
consistency. And it ignored the opinions of the authors of those studies, and of 11
independent scientists who reviewed those studies, that they could support a 12
finding of consistency. 13
Take the first of these studies, Ji 2020, which measured the association 14
between acetaminophen detected in the umbilical cord at birth and ASD diagnosis 15
and found a statistically significant increase in ASD diagnoses among children in 16
the highest tertile of acetaminophen exposure, compared to the lowest. Id. at 343. 17
Baccarelli did acknowledge the limitations of this study: for example, that 18
acetaminophen detected in the umbilical cord at the time of birth would reflect 19
only peripartum exposure (i.e., exposure at the time of or in the hours before birth), 20
and acetaminophen was detected in 100% of mothers measured, “which 21
contradicts the common knowledge that only about half of pregnant women take 22
acetaminophen, and certainly much less during the peripartum period.” App’x 23

-- 45 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
46
1833. That, according to Baccarelli, could mean that that the study included false- 1
positives based on environmental exposures to acetaminophen (e.g., in drinking 2
water) or that the authors included values detected below the assay’s detection 3
limit (i.e., the minimum concentration that can, in a statistically significant 4
manner, be distinguished from zero). See App’x 1843–44. But he went on to point 5
out why the study’s limitations would not detract from interpreting the study as 6
some support for the consistency criterion. For example, he explained that the 7
measurement of acetaminophen “may not fully reflect prenatal exposure to 8
acetaminophen”—which would mean that Ji 2020 might actually underestimate the 9
effect of total prenatal exposure. App’x 1844. And on the issue of extra-sensitive 10
acetaminophen detection, he noted that because the authors performed a tertile 11
analysis on low, medium, and high exposure, false positives with minimal levels 12
of exposure would have been grouped together in the low category—which would 13
have protected against bias introduced by those false positives. See App’x 1844. 14
To be clear, the limitations in Ji 2020 are not insignificant and certainly go to 15
the weight that the fact-finder may attribute to Baccarelli’s testimony on this 16
evidence. But they do not render the study “largely irrelevant,” as the district court 17
suggests. 707 F. Supp. 3d at 343. Nor do they prevent Baccarelli from interpreting 18
the study as supportive of the consistency criterion. Baccarelli’s reliance on Ji 2020, 19
like the rest of his opinion, can be tested by cross-examination, contested by 20
opposing experts who may evaluate the evidence differently, and forcefully 21
advocated for and against by the parties’ attorneys. We hold only that Bacarrelli’s 22
report acknowledges the limitations of the study and gives a scientific explanation 23

-- 46 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
47
of his reasons for finding the study consistent as demanded by the accepted 1
Bradford Hill methodology. 2
The second study, Liew 2016a26, found an association between 3
acetaminophen and ASD with hyperkinetic disorder (“HKD”), a condition 4
recognized under the World Health Organization’s International Classification of 5
Diseases that is analogous to a severe ADHD diagnosis under the DSM. See Liew 6
2016a at 952. That study too has limitations. For example, it found no association 7
between acetaminophen and ASD without HKD. And in its analysis of trimester- 8
specific exposure, it found statistically significant associations for acetaminophen 9
use in all three trimesters, and the first and second trimesters combined, but not 10
the second and third combined or first and third combined. Such limitations, the 11
district court reasoned, constitute conflicting results that undermine consistency. 12
See 707 F. Supp. 3d at 343–44. But again, Baccarelli addressed those limitations. 13
And for reasons he explains, he concluded that they did not preclude a finding of 14
consistency with other literature. For example, he adopted the authors’ own 15
acknowledgment that ASD with hyperkinetic features may be a subtype of ASD, 16
rather than a different diagnosis altogether. App’x 1841. And, with respect to the 17
issue of variable trimester-specific results, Baccarelli explained that “a set of results 18
is consistent even if some of the results are not statistically significant.” App’x 19
26 Liew et al., Maternal Use of Acetaminophen During Pregnancy and Risk of Autism Spectrum Disorders
in Childhood: A Danish National Birth Cohort Study, 9 Autism Rsch. 951 (2016). The district court referenced
three articles published by Liew in 2016. We need only address the one it referred to as “Liew 2016a.”

-- 47 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
48
1769.27 Indeed, Liew 2016a found uniformly positive associations with 1
acetaminophen exposure by trimester and ASD, ranging from 1.03 (first trimester 2
exposure only) to 1.39 (exposure in all three trimesters). The varying statistical 3
significance of those results does not necessarily render them inconsistent for the 4
purpose of the Bradford Hill analysis. As a result, it was not improper for 5
Baccarelli to cite Liew 2016a in support of the consistency criterion. 6
In the end, Baccarelli’s testimony on consistency is consistent with the 7
findings of the studies that he cites. For example, the authors of Ji 2020 noted that 8
its findings “support previous studies regarding the association between prenatal 9
and perinatal acetaminophen exposure and childhood neurodevelopment risk.” Ji 10
2020 at 180. The authors of Avella-Garcia 2016, another study he examines, 11
conclude that their findings “agree with reports of an association between prenatal 12
exposure to acetaminophen and ADHD behaviours, diagnosis or medication use 13
in childhood.” Avella-Garcia 2016 at 1993. And the authors of Liew 2016a noted 14
that their findings built upon earlier work showing that “prenatal exposure to 15
acetaminophen may increase[] the risk of developing hyperkinetic disorders and 16
social and behavioral problems.” Liew 2016a at 954. That the above scientists 17
operating outside the courtroom also interpret these studies as consistent with 18
other findings of an association supports Baccarelli’s conclusion that the 19
consistency criterion is sufficiently satisfied. 20
27 See also App’x 1799–1800 (“[E]pidemiologists are often less concerned with the precise p-value
[which may suggest a yes/no answer that cannot be inferred from a single study] and more interested in
understanding whether the results are consistent with what we know about the biology of the disease or
exposure being studied.”).

-- 48 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
49
To be clear, an expert’s testimony is not reliable simply because other 1
scientists have expressed the same view in a peer-reviewed publication. Just as 2
evidence of disagreement among scientists as to the correct interpretation of a 3
body of evidence does not necessarily render an expert’s opinion unreliable, 4
expressions of support for an opinion, without more, do not necessarily qualify 5
the opinion as reliable. Rather, the district court must take a “hard look” at the 6
literature an expert cites to determine whether that literature actually reflects how 7
experts operate in the field or if it merely presents a one-off opinion that the field 8
has roundly rejected or would be likely to. And that, we believe, the district court 9
did not adequately do by substituting its own judgment of the evidence on an issue 10
where scientists may reasonably disagree. 11
Further, the district court similarly censured Baccarelli’s discussion of the 12
strength factor. There, Baccarelli opined that because the magnitude of the risk 13
ratio in many studies may have been dampened due to reliance on maternal self- 14
reporting, the strong association found in Baker 2020—which directly measured 15
acetaminophen levels in the child’s meconium—provided strong evidence in 16
support of the strength criterion. The district court noted, however, that that study 17
“had not controlled for confounding by either indication or genetics.” 707 F. Supp. 18
3d at 348. And it held that Baccarelli’s testimony on the strength criterion was 19
insufficient in part because he failed to examine that limitation. 20
There are two problems with that holding. First, Baccarelli did address the 21
issue of confounding in the Baker 2020 study. He explained that the effect size 22
found in Baker 2020 is “so large” that “residual confounding by uncontrolled 23

-- 49 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
50
factors is a less likely explanation for the identified associations”—a conclusion 1
that the authors of the Consensus Statement agreed with. App’x 1902 (internal 2
quotation marks omitted). And second, while Baccarelli did not include an 3
extensive discussion of genetic confounding in his analysis of the strength 4
criterion, he did perform that analysis elsewhere in his expert testimony. For that 5
reason, it does not surpass the limitations in Baker 2020 to conclude that it, in 6
combination with other studies that do control for confounding, can be relied on 7
in support of a plausible causal relationship. 8
For the above reasons, we conclude that the district court erred in excluding 9
Baccarelli’s testimony. While the district court’s reasoning was considered and 10
extensive, its analysis frequently overstepped its gatekeeping function by 11
substituting its own judgments about the requirements of causality and the 12
persuasiveness of various studies for those of scientists operating in the field. As 13
a result, it ignored that Baccarelli acted in accordance with how scientists approach 14
the question of causation using the Bradford Hill method and have previously 15
interpreted the literature upon which he relied. When an expert reliably applies a 16
scientifically accepted methodology on an issue that is reasonably subject to 17
debate, it is for the jury to decide the opinion’s correctness.28 18
28 Because we conclude that Baccarelli’s Bradford Hill analysis is admissible, we need not address
Baccarelli’s Navigation Guide, the application of which yielded the same conclusion. We express no
opinion on the reliability of the Navigation Guide as a methodology or Baccarelli’s application of it.

-- 50 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
51
2. Hollander 1
Hollander’s initial report focused primarily on the appropriateness of 2
analyzing ASD, ADHD, and related NDDs together in a transdiagnostic analysis, 3
providing support for Baccarelli’s Bradford Hill analysis. In doing so, he explained 4
the “considerable genetic, neuropsychological and clinical overlap” between the 5
two disorders. App’x 2533. The district court excluded that opinion in its entirety.29 6
It acknowledged that Hollander offered a “reliable assessment of the literature” 7
on the overlap between ASD and ADHD but faulted him for failing to explain how 8
a transdiagnostic Bradford Hill analysis should be structured and concluded that 9
the studies he cited did not adequately support the conclusion that the scientific 10
community would accept a Bradford Hill analysis that assessed ADHD and ASD 11
together. 707 F. Supp. 3d at 364. But, as explained above, scientists have in fact 12
analyzed the disorders together, and Hollander’s discussion, while not necessary 13
to justify Baccarelli’s transdiagnostic approach, provides helpful context as to the 14
relationship between ASD and ADHD. 15
In addition, the district court dismissed Hollander’s reliance on certain 16
scholarship explaining the value of a transdiagnostic perspective because those 17
articles were “irrelevant” to the “transdiagnostic Bradford Hill analyses presented 18
by” Baccarelli and Cabrera. 707 F. Supp. 3d at 366. But the district court adopted 19
an unduly narrow definition of relevance. For example, Hollander cites 20
29 Hollander also offered a biological plausibility opinion in his opening report and a Bradford Hill
analysis in his rebuttal report, both of which the district court excluded. Plaintiffs-Appellants do not appeal
those exclusions here, so we do not discuss them.

-- 51 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
52
Vandewouw 202330 in support of considering ADHD and ASD together in a single 1
causal analysis. Proceeding from the understanding that ASD, ADHD and OCD 2
“are highly heterogenous in biology and phenotype [i.e., observable 3
characteristics] within each condition and significantly overlapping,” the study 4
reviewed brain scans of individuals diagnosed with those conditions and found 5
that differences in brain function corresponded to differences in behavior (e.g., 6
hyperactivity and impulsivity) but not differences in clinical diagnoses. Thus, the 7
authors concluded that their finding put pressure on the field’s reliance “on 8
diagnostic categories, which have increasingly been shown not to reflect distinct 9
biological and phenotypic constructs.” The district court criticized Hollander’s 10
reliance on the study because, while it is generally supportive of his position, it 11
did not establish in definitive terms that proof of a causal relationship between 12
acetaminophen and ADHD suffices as proof of a causal relationship between 13
acetaminophen and ASD. 707 F. Supp. 3d at 366. But as Hollander’s testimony 14
shows, scientists in this field require no such proof to conduct a transdiagnostic 15
analysis. As he explains, the transdiagnostic approach may be appropriate when, 16
as here, “[t]he biological factors behind the[] symptoms cut across traditional 17
diagnostic boundaries” such that “a holistic and transdiagnostic approach . . . is 18
necessary to fully understand the highly heterogenous conditions” at issue. App’x 19
2482–83. The district court therefore overstepped its gatekeeping function in 20
30 Vandewouw et al., Identifying Replicable Subgroups in Neurodevelopmental Conditions Using Resting-
State Functional Magnetic Resonance Imaging Data, 6(3) JAMA Network Open: e232066 (2023).

-- 52 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
53
excluding Hollander’s testimony on the appropriateness of considering ASD, 1
ADHD, and NDDs in a single Bradford Hill analysis. 2
3. Pearson 3
Pearson opined that a causal relationship between prenatal acetaminophen 4
exposure and ADHD and ASD is consistent with existing biological knowledge 5
based on preclinical literature, focusing primarily on animal studies. He concluded 6
that the majority of preclinical studies demonstrate that acetaminophen has 7
disruptive effects on neurodevelopment through multiple independent and 8
interacting mechanisms, and that these studies support findings of a possible 9
causal association between prenatal acetaminophen use and ADHD and ASD 10
observed in epidemiological studies of humans. In his report, he acknowledges 11
inconsistencies among the studies that he analyzes, including in the directionality 12
of the effects observed—for example, that acetaminophen exposure may cause an 13
increase in a particular behavior among some subjects, and a decrease in that 14
behavior among other subjects. He explains, though, that “the heterogeneity of the 15
results is not a reason to dismiss the effects of APAP shown in these individual 16
studies,” because “neurodevelopmental perturbation of prenatal APAP can 17
manifest in various ways in terms of directionality.” App’x 2144. The district court 18
decided that this conclusion rendered Pearson’s testimony unreliable because it 19
amounted to an unreasonable conclusion that “heterogeneity and outright 20
inconsistency of results don’t ultimately matter,” and because his conclusion to 21
this effect was not adequately supported. 707 F. Supp. 3d at 369. 22

-- 53 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
54
The district court erred in excluding Pearson’s testimony on these grounds. 1
Admittedly, it seems counterintuitive, for example, that a study observing a 2
decrease in hyperactivity among acetaminophen-dosed rodents may evidence that 3
the same treatment causes an increase in ADHD among humans. But Pearson’s 4
point is not unreasonable: Any behavioral evidence of neurodevelopmental 5
change attributable to acetaminophen supports the conclusion that 6
acetaminophen disrupts neurodevelopment. And his testimony to that effect is 7
more nuanced and limited than the district court concludes. 8
First, Pearson was not without support for his contention. He cited Tyl 9
200831, a guidance document that provides a framework for reliably interpreting 10
animal studies. That framework explains, as Pearson quotes, that “[v]ariability” in 11
test results “can be interpreted as an endpoint itself rather than an indicator of 12
study quality or reliability, and may be the first or most sensitive indicator of a 13
response.” App’x 2096. 14
Moreover, Pearson does not suggest that such inconsistent results 15
nonetheless provide support for a causal conclusion. Rather, Pearson asserts that 16
when such inconsistencies appear, it is appropriate “to try to understand and 17
explain the reasons for them, possibly deciding if more than one answer to the 18
formulated problem is plausible.” App’x 2098. This is consistent with Tyl 2008’s 19
guidance, which Pearson cites, that “[p]roper interpretation involves expert 20
31 Tyl et al., Identification and Interpretation of Developmental Neurotoxicity Effects: A Report from the
ILSI Research Foundation/Risk Science Institute Expert Working Group on Neurodevelopmental Endpoints, 30
Neurotoxicology and Teratology 349 (2008).

-- 54 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
55
judgment that takes into account both the biological and statistical significance of 1
the results.” App’x 2096, 4875. 2
Pearson took exactly that approach in evaluating the studies. For example, 3
in his analysis of in vitro/ex utero studies examining the relationship between 4
acetaminophen exposure and neurotoxicity, he identified three studies that found 5
no evidence of neurotoxicity and five studies that found evidence of neurotoxicity. 6
App’x 2140. He concluded that, overall, those studies supported an association 7
between acetaminophen exposure and neurotoxicity. But he did not ignore the 8
studies that seemed to contradict that conclusion. For example, he explained that 9
one study that found no association failed to evaluate metabolized 10
acetaminophen, which provides a separate hypothesized mechanistic pathway. 11
App’x 2135. Another study found no neurotoxic outcomes in rat cortical cultures 12
where APAP was administered on the third day in vitro. Pearson noted, however, 13
that the relevant cortical cultures do not mature until at least the seventh day in 14
vitro, such that testing on the third day is “potentially too early or at least might 15
need to be interpreted carefully.” App’x 2137. And the third study finding no 16
neurotoxicity was designed to test the effect of other chemicals, with 17
acetaminophen acting as a putatively non-neurotoxic control, such that the 18
treatment dose size was too small to prompt neurotoxic effects. App’x 2137. 19
Whether Pearson’s conclusions are ultimately persuasive is not for us to decide. 20
What we do decide is that he cannot fairly be found to have ignored evidence 21
contrary to his conclusions, or engaged in unscientific sophistry, where he did 22
discuss the contrary evidence and presented his reasons for discounting it, simply 23
because a court disagrees with those reasons. 24

-- 55 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
56
4. Cabrera 1
Cabrera testified on the reproductive, developmental, and 2
neurodevelopmental toxicity of prenatal acetaminophen exposure. First, Cabrera 3
described a proposed biological mechanism by which acetaminophen could cause 4
ADHD and ASD. Cabrera based this mechanism on an Adverse Outcome Pathway 5
(“AOP”) addressing oxidative stress. An AOP is a model which, in Cabrera’s case, 6
was published by the Organization for Economic Co-operation and Development 7
(“OECD”). It describes a logical sequence of causally linked events at various 8
levels of biological organization, beginning with exposure to a particular stressor 9
and leading to an adverse health effect.32 Cabrera first assessed the evidence for 10
each step in the causal pathway using a weight-of-the-evidence approach and then 11
opined that the association between prenatal acetaminophen exposure and ADHD 12
and ASD was biologically plausible. Plaintiffs-Appellants did not fully brief the 13
district court’s exclusion of that testimony, so we do not address it here.33 14
Next, Cabrera opined that each of the Bradford Hill criteria, with the 15
exception of specificity, were satisfied, thereby supporting a determination of 16
32 See OECD, OECD Series on Adverse Outcome Pathways,
https://www.oecd.org/en/publications/oecd-series-on-adverse-outcome-pathways_2415170x.html. Other
entities utilize AOP models as well. See, e.g., EPA, Adverse Outcome Pathways,
https://www.epa.gov/chemical-research/adverse-outcome-pathways (describing how the EPA uses AOP
models); National Toxicology Program, U.S. Dep’t Health & Hum. Serv., Adverse Outcome Pathways,
https://ntp.niehs.nih.gov/whatwestudy/niceatm/comptox/ct-aop/aop.
33 The district court determined that Cabrera’s weight-of-the-evidence analysis was applied
unreliably as to (1) the initiation of the AOP by acetaminophen exposure and (2) the connection between
the final step in the AOP and diagnosis with ADHD and/or ASD. Plaintiffs-Appellants addressed the first
gap in their appeal to this Court but not the second—so even if we were to reinstate the first link, the
testimony could remain excluded.

-- 56 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
57
causality. The district court determined that this testimony was unreliable because 1
Cabrera failed to address the relationship between the factors or explain the 2
weight that he attached to each one. The district court was within its discretion in 3
doing so. 4
A scientist need not find every one of the nine Bradford Hill criteria satisfied 5
in order to opine reliably that a causal relationship exists. For example (and as 6
explained above with regard to Baccarelli), if found to be present, the specificity 7
criterion may be especially powerful evidence of causality, but its absence does 8
not exclude a finding of plausible causality. Similarly (and as also explained 9
above), while an especially strong association between an exposure and outcome 10
may serve as strong evidence of a causal relationship, a weak association doesn’t 11
necessarily mean that no causal relationship is present. That is particularly so 12
when there is a good explanation for the observed magnitude—such as broad 13
exposure to the toxin of interest, as in the case of air pollution or secondhand 14
smoke, or mediating factors that contribute to the ultimate outcome in some but 15
not all cases, such as genetic predispositions to a particular outcome. Because of 16
these nuances in the interpretation of the various Bradford Hill criteria, the factors 17
do not function as independent check-boxes, which are added to indicate the 18
strength of a causal relationship. Instead, as multiple courts have recognized, 19
expert analysis is necessary to understand how a particular combination of criteria 20
does or does not support the ultimate causal conclusion. See, e.g., Daniels-Feasel, 21
2023 WL 4837521, at *2, quoting Zoloft, 858 F.3d at 796 (“To ensure that the 22
Bradford Hill/weight of the evidence criteria ‘is truly a methodology, rather than 23
a mere conclusion-oriented selection process . . . there must be a scientific method 24

-- 57 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
58
of weighting that is used and explained.’”); In re Mirena (No. II), 341 F. Supp. 3d at 1
248 (“[W]here experts have claimed to apply Bradford Hill, courts have insisted 2
on a clear explication of the weighting assigned to the different criteria.”). 3
That analysis is particularly necessary to enable a factfinder to “conduct[] a 4
meaningful and informed review.” In re Mirena (No. II), 341 F. Supp. 3d at 249. 5
Were a factfinder to disagree with any one of Cabrera’s conclusions, for example, 6
she “would then need to assess whether to find general causation in the absence 7
of [that] factor[].” Id. By not “explain[ing] the relationship among the factors in his 8
analysis, however,” Cabrera “disable[s] such an inquiry.” Id. at 248. As a result, 9
the district court was permitted to conclude that Cabrera’s application of the 10
Bradford Hill method was unreliable and therefore inadmissible under Rule 702.34 11
5. Louie 12
Louie discussed the dose and duration at which prenatal exposure to 13
acetaminophen increases the risk that a child will develop ADHD and/or ASD. He 14
concluded that the epidemiological evidence provides a “clear answer”: exposure 15
“for at least 28 cumulative days during pregnancy increases the risk of 16
ASD/ADHD development by two-fold as compared to offspring with no exposure 17
to acetaminophen.” App’x 2737, 2739. The district court excluded Louie’s 18
testimony on the grounds that he misstated certain evidence upon which he relied 19
34 Plaintiffs-Appellants admittedly offer some support in the record for the proposition that
scientists do not necessarily regard such weighing as mandatory, but we cannot say that the district court
exceeded its discretion in relying on a proposition amply and directly supported by caselaw and that is
meant to help a factfinder evaluate an expert’s opinion.

-- 58 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
59
and failed to justify adequately the conclusions that he drew from his review of 1
the literature. The district court did not abuse its discretion in doing so. 2
First, Louie did not treat the studies he examined with requisite care. For 3
example, he concluded that “studies by Brandlistuen et al, Ystrom et al, and 4
Gustavson et al[] found that acetaminophen exposure beyond 28 days showed a 5
two-fold increased risk for childhood ADHD and ASD diagnosis.” App’x 2757. 6
Not so. Ystrom and Gustavson examined the relationship between acetaminophen 7
exposure and ADHD diagnosis, but not ASD. And Brandlistuen did not examine 8
diagnoses of either ASD or ADHD but instead looked at the relationship between 9
acetaminophen exposure and neurodevelopmental outcomes that are themselves 10
connected to ASD and ADHD. As discussed earlier, it is not necessarily unreliable 11
to consider ADHD and ASD together, or to examine symptomatic endpoints as 12
well as diagnostic ones. But it is proper to exclude testimony that mischaracterizes 13
a study. 14
Louie also failed to substantiate significant assumptions on which his 15
testimony rested. This error is most apparent in Louie’s conclusion pertaining to 16
the relevant exposure threshold. Louie testified that Brandlistuen 2013, Ystrom 17
2017, and Gustavson 2021 “all found that acetaminophen exposure beyond 28 days 18
showed a two-fold increased risk for childhood ADHD and ASD diagnosis.” 19
App’x 2757. But that is either a misinterpretation of those studies’ findings, or an 20
impermissibly imprecise extension of them. Each of those studies examined the 21
frequency of the measured outcome among mothers who ingested acetaminophen 22
for more than 28 or 29 days, compared to those who did not ingest any 23

-- 59 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
60
acetaminophen. The “twofold risk” that each study found, therefore, was not the 1
risk associated with ingesting acetaminophen with any frequency beyond the 2
twenty-eight day threshold, as Louie concludes. It was, instead, the average risk 3
associated with prenatal acetaminophen exposure among the group of mothers 4
who ingested acetaminophen for between twenty-eight and two-hundred eighty 5
days, the length of an entire pregnancy. As a result, the district court was entitled 6
to exclude Louie’s testimony because “there is simply too great an analytical gap 7
between the data and the opinion proffered.” Joiner, 522 U.S. 136, 146 (1997). 8
*** 9
As explained above, the district court erred in dismissing expert testimony 10
from Baccarelli, Hollander, and Pearson. It therefore follows that the district court 11
also erred in granting summary judgment for Defendants-Appellees on the basis 12
that Plaintiffs-Appellants lacked any evidence of general causation. 13
C. Preemption 14
As an alternative basis for affirmance, Defendants-Appellees argue that 15
federal law preempts the failure-to-warn claims raised here. For the reasons 16
articulated by the district court in its excellent analysis of the issue, we do not 17
agree. 18
The Supremacy Clause provides that federal law “shall be the supreme Law 19
of the Land.” U.S. const. art. VI, cl. 2. Consistent with that command, “[w]here 20
federal and state law conflict—that is, where it is impossible for a party to follow 21
both federal and state law—state law must give way.” Gibbons v. Bristol-Myers 22
Squibb Co., 919 F.3d 699, 708 (2d Cir. 2019). “When addressing federal preemption 23

-- 60 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
61
questions, ‘we have long presumed that Congress does not cavalierly pre-empt 1
state-law causes of action.’” Marentette v. Abbott Laboratories, 886 F.3d 112, 117 (2d 2
Cir. 2018), quoting Medtronic, Inc. v. Lohr, 518 U.S. 470, 485 (1996). We therefore 3
“start with the assumption that the historic police powers of the States [are] not to 4
be superseded . . . unless that [is] the clear and manifest purpose of Congress.” 5
Wyeth, 555 U.S. at 565 (internal quotation marks omitted). 6
Defendants-Appellees contend that the FDA’s Pregnancy Warning 7
Regulation creates an exclusive process for adding pregnancy-related warnings to 8
drug labels. Thus they assert that they could give a specific warning on ADHD 9
and ASD if, and only if, the FDA requires one through the IAAA monograph or 10
an NDA. But this is plainly not what the text of the Pregnancy Warning Regulation 11
commands. The Regulation requires manufacturers to display the general warning 12
or, when one is provided by the FDA, a specific warning. It does not prohibit 13
manufacturers from adding supplemental warnings when additional, pregnancy- 14
related risks become known. And it does not modify the manufacturer’s ultimate 15
responsibility for the accuracy and adequacy of their label. 16
Defendants-Appellees look next to the Exact Language Regulation for 17
support. But the Exact Language Regulation applies only where exact language 18
has been specified, and as such, has no bearing on the addition of supplemental 19
warnings. Defendants-Appellees can readily comply with the Pregnancy Warning 20
Regulation and Exact Language Regulation, while warding off any failure-to-warn 21
claims, by providing the general pregnancy warning verbatim, as specified in 21 22
C.F.R. § 201.63, and a supplemental warning about any additional risk of ADHD 23

-- 61 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
62
and ASD. “Impossibility pre-emption is a demanding defense,” Wyeth, 555 U.S. at 1
573, and Defendants-Appellees have not shown that simultaneous compliance 2
with the federal Pregnancy Warning Regulation and state law warning 3
requirements is impossible.35 4
D. Plaintiffs-Appellants’ Remaining Arguments 5
Plaintiffs-Appellants in Phippen make two additional arguments. First, they 6
contest the exclusion of their expert, Ness, whom they introduced to testify to 7
general causation and ADHD after the district court excluded Baccarelli, 8
Hollander, Pearson, Cabrera, and Louie. Second, they argue that even if all their 9
35 Defendants further argue that the history of the Pregnancy Warning Regulation shows that it
preempts any requirements under state law. When the FDA first introduced the regulation in 1982, it
explained that competing regulations from other states could “weaken [its] efforts to develop
comprehensive national labeling and other requirements for OTC drugs” and wanted to ensure that
manufacturers could “use the new FDA labeling without also being required to use the pregnancy-nursing
warning required by any State.” Pregnant or Nursing Women, 47 Fed. Reg. 54750, 54756–57 (Dec. 3, 1982)
Admittedly, those statements indicate that the agency may have thought it wise for the Pregnancy Warning
Regulation to preempt other state-law requirements, but the plain language certainly does not require that
conclusion. See Safe Haven Home Care, Inc. v. United States Dep’t of Health & Hum. Servs., 130 F.4th 305, 315
(2d Cir. 2025) (explaining that “we need not defer to the agency’s interpretation of its own regulation”
when “the regulation is unambiguous”). Moreover, the agency’s subsequent actions appear to disavow any
such intention. As noted above, in 1999, the agency issued a comprehensive rule governing OTC drug
labeling, which, in part, amended the Pregnancy Warning to its present form. See Over the Counter Drugs,
64 Fed. Reg. at 13286. Prior to issuing the final rule, the agency had considered including a provision that
would “preempt State and local rules that establish different requirements than those in the proposed rule,
to promote a national, standardized format for all OTC drug product labeling.” Id. at 13254. It ultimately
decided not to enact such a rule because Congress, in the interim, had passed the Food and Drug
Administration Modernization Act of 1997 (“FDAMA”). That new law included a provision governing
preemption, which the FDA decided it would rely on “in addressing preemption issues.” Id. at 13272, citing
21 U.S.C. § 379r. The provision bans states from enacting any labeling requirement “that is different from
or in addition to” those required by the FDA, but it contains a carveout for state products liability law:
“Nothing in this section shall be construed to modify or otherwise affect any action or the liability of any
person under the product liability law of any State.” 21 U.S.C. § 379r(a), (e). The FDA’s decision to adopt
the preemption approach outlined in the FDAMA thus undercuts any continued relevance of its 1982
statement.

-- 62 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
63
experts remain excluded, statements made by Defendants-Appellees’ expert, 1
Faraone, which are supportive of a possible causal relationship between prenatal 2
acetaminophen exposure and ADHD, would be sufficient to permit a jury to 3
conclude in Plaintiffs-Appellants’ favor on the issue of general causation. 4
Their first argument is one that, in the interest of judicial economy, we do 5
not reach today. The Phippen Plaintiffs-Appellants offered Ness only after the five 6
Rutledge experts were excluded, and only to support the limited proposition of a 7
causal relationship between prenatal acetaminophen exposure and ADHD. 8
Because Baccarelli, Hollander, and Pearson’s opinions are admitted, the Phippen 9
Plaintiffs-Appellants may well wish to proceed at this time without Ness’s 10
testimony. Moreover, without expressing any opinion about the correctness of the 11
district court’s rejection of Ness’s testimony, to the extent the Phippen Plaintiffs- 12
Appellants do decide to press ahead with Ness as an additional expert witness, the 13
district court, informed by our analysis above, may well choose to revisit its 14
conclusions about her testimony. We therefore express no opinion on its 15
admissibility, vacate the district court’s judgment in Phippen, and remand to allow 16
further proceedings consistent with this opinion. 17
Second, the Phippen Plaintiffs-Appellants contend that a jury could find 18
general causation based on certain statements made by Faraone, namely fragments 19
from his deposition, his scientific papers, and his popular science writings that, 20
read in isolation, could be construed as evidence in support of a causal relationship 21
between prenatal acetaminophen exposure and ADHD. Even if all of the 22
statements identified by Plaintiffs-Appellants are deemed admissible, this 23

-- 63 of 64 --

24-916(L); 24-2594
Rutledge v. Walgreen Co.; Phippen v. Walgreen Co.
64
“concatenation of scientific propositions” falls far short of reliable expert 1
testimony upon which a jury may find general causation. In re Mirena IUS 2
Levonorgestrel-Related Prods. Liab. Litig. (No. II), 387 F. Supp. 3d 323, 354 (S.D.N.Y. 3
June 11, 2019). The district court correctly determined that, “[e]ven if cobbled 4
together, the Faraone [statements] do[] not constitute a Bradford Hill analysis in 5
support of plaintiffs’ thesis.” In re Acetaminophen, 2024 WL 3874183, at *4. 6
III. Conclusion 7
In this opinion, we have assessed the admissibility, and only the 8
admissibility, of the opinions of Plaintiffs-Appellants’ experts. We have not 9
assessed the weight they should be given by a factfinder. Defendants-Appellees’ 10
experts are not before us. We do not prejudge whether the expert testimony 11
discussed here, when considered in light of the totality of the evidence, including 12
any admissible testimony from Defendants-Appellees’ experts, suffices to raise an 13
issue of fact for summary judgment purposes. Moreover, we have considered the 14
record as it was before the district court. Since the district court’s decision, 15
numerous relevant studies on this issue have been published. The district court 16
may consider it prudent to invite the parties and their experts to address those 17
new studies. 18
For the reasons explained above, we VACATE the district court’s judgments 19
and REMAND for further proceedings consistent with this opinion. 20

-- 64 of 64 --